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ABSTRACT 
Effrat Libby Fayer: The Design and Application of Peptides and Synthetic Receptors to 
Chemical Biology 
(Under the direction of Marcey Waters) 
 
The need for chemical tools to probe biological process has become increasingly apparent 
in the last decade. The work presented here focused on developing such tools, taking on two 
different paths of development-one using supramolecular chemistry to aid in proteomics, a 
highly popular focus of research, and the other making use of peptides to create reporters with 
the ability to probe enzyme activity in cells. 
Posttranslational Modifications (PTMs) of proteins are implicated in a wide range of 
biological processes, including gene transcription, DNA replication and repair, mitosis, and 
meiosis.1 Consequently, their dysregulation is linked to various diseases, including cancer, 
asthma, and diabetes, among others, and can thus serve as valuable diagnostic indicators of 
disease progression.1,2 Due to these biological ramifications, there is great interest in mapping 
where, when, why, and how PTMs are installed and their subsequent downstream effects, though 
this is often hampered by their presence in complex mixtures, consisting of mostly un-modified 
proteins/peptides. 
 Using synthetic supramolecular receptors developed in our lab,3 an affinity 
chromatography based method is described here that allows for the separation/enrichment of 
posttranslationally methylated peptides from such mixtures. This takes advantage of the 
receptor’s greater affinity towards methylated lysine over its non-methylated counterpart. When 
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attached to a solid support, the receptors can be used to make a column, through which peptides 
will travel at different rates based on the methylation states of lysine residues. This allows for the 
separation of these peptides, drastically simplifying their detection and analysis. 
Just as important as PTMs are the enzymes that install them. Dysregulation of various 
enzymatic pathways is implicated in many diseases. The ability to monitor enzyme activity 
within cells is becoming increasingly important, for promoting further discovery, as well as to 
enable early detection and patient monitoring during treatment. The use of peptide substrates for 
such assays is extremely advantageous, as they are the best mimics of the enzymes’ natural 
substrates. Furthermore, the ease of synthesizing peptides allows them to be easily modified for 
specialized function and detection, making them applicable to multiple types of assays.4 While 
they work quite well for in vitro assays, they are incompatible with the cytosolic environment, as 
they are rapidly destroyed by cytosolic peptidases.5 
 In this dissertation, a variety of approaches towards increasing the lifetime of peptides in 
cytosolic environment were tested. Kinase substrates were selected as test peptides due to their 
role in a diverse set of vital processes, and their importance in current drug development efforts. 
For the most successful method, the rates of proteolytic degradation in cell lysates and in vitro 
phosphorylation were measured and analyzed using capillary electrophoresis paired with laser 
induced fluorescence (CE-LIF). Comparison to unmodified substrate peptides was used to assess 
the effect of dimerization on protease resistance and substrate efficacy. Finally, a dimerized Abl 
kinase substrate was used to monitor phosphorylation in living cells, demonstrating the utility of 
this method for intracellular assays. We find that N-terminal dimerization provides comparable 
half-lives to the best previously reported methods, with significantly greater synthetic 
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accessibility, suggesting that this is a promising new method for developing peptide-based 
intracellular probes. 
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Chapter I. The Use of Peptides as Reporters to Monitor Enzymatic Activity 
 
1. Introduction 
The understanding of disease has evolved markedly over the last two centuries. With the 
rapid advancements in analytics and the mapping of the human genome and proteome, scientists 
have gone from merely treating external symptoms to the point of understanding them on the 
molecular level. Dysregulated enzymes are now known to be notorious culprits in the causation 
and progression of many diseases, and with this knowledge at hand, it has become increasingly 
important to develop biosensors that allow us to monitor their activity. Such tools are extremely 
useful for fundamental studies, allowing scientists to tackle questions concerning the function of 
enzymes, as well as subsequent use of that knowledge to develop mimics or derivatives for the 
purpose of binding and/or catalysis. Drug discovery also heavily relies on the toolbox of probes 
for high throughput screening (HTS) of drug candidates and subsequent analysis of their 
therapeutic efficacy.6 An expansion of the toolbox is foreseen to extend its use into biomedical 
applications, including diagnostic assays and monitoring of disease progression and response to 
therapeutics in patients. This area of research has recently sparked the interest of the scientific 
community and the addition of new analytical techniques has advanced at a rapid pace. In this 
chapter, examples of biosensors used to monitor enzyme activity will be discussed, focusing on 
peptide-based probes. 
2. Peptides as substrates for the detection of enzymatic activity 
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Enzymatic activity is traditionally analyzed by radiolabeling, where incorporation of a 
radioactive moiety into a substrate is quantified by scintillation counting, or by a number of 
antigenic approaches, such as Western blotting, enzyme-linked immunosorbent assay (ELISA), 
and immunohistochemistry. Aside from radiolabeling, which has the obvious problem of having 
to handle radioactive waste, these methods all rely on antibodies for recognition. This can be 
seen as a disadvantage since they are expensive and difficult to produce, and batch to batch 
variability can be the source of misleading results.7 The post reaction analysis required with 
these methods is also quite time consuming, and while they can provide significant information, 
they give only indirect measurement of catalytic activity, and are not able to provide real-time 
kinetic data.8 For investigating cell lysates, all of the above methods suffer from the additional 
disadvantage of requiring a large number of cells. In the context of biomedical applications, this 
can become problematic, as obtaining large samples from patients can be challenging, and even 
detrimental to the patient. 
The use of peptide-based reporters for enzymatic assays has begun to overcome some of the 
aforementioned limitations. Peptides are excellent mimics of the enzymes’ natural substrates, 
making them particularly effective as probes for enzymatic activity. They can be designed with 
high affinity and specificity to the enzyme of interest, or alternatively, as non-selective substrates 
for an enzyme family, if so desired.4 Peptides further carry the advantage of being easy to 
synthesize and modify, by hand or by automated synthesis, and cost effective. Finally, peptide 
substrates can provide a direct readout, allowing one to monitor enzyme reactions in real-time. 
Numerous approaches have been developed to pair such substrates with a detectable readout, 
including the use of electrochemical,9–16 colorimetric,17 and element mass spectrometry18 output, 
though those will not be discussed here (for further examples, see Liu et al.19 and Pavan et al.20). 
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Instead, the focus here will be on using fluorescent peptide-based reporters. The addition of a 
fluorophore to a peptide substrate allows for rapid sensitive detection that can be visualized and 
quantified by various types of instrumentation, including fluorescence microscopy, liquid 
chromatography with fluorescence detection, and capillary electrophoresis paired with laser 
induced fluorescence (CE-LIF). Within that category alone, a number of approaches have 
already been taken in translating enzyme activity into readable output. A few of the most popular 
ones are described below, followed by the work being done to apply those to intracellular assays. 
Approaches to reading fluorescent peptide-based probes 
The use of solvatochromic fluorophores conjugated to peptide substrates has been extremely 
popular in kinase assays. 21 Solvatochromic fluorophores are ones whose spectroscopic 
properties change in response to changes in the polarity 
of their surrounding environment. When placed in 
proximity to a target residue on a peptide substrate, 
modification of the peptide by an enzyme, or a 
subsequent event, such as recruitment of a reader 
protein (Figure 1), can lead to a change in fluorescence. 
Examples of this can be seen in probes developed for 
PKC,22 Src, 23  and cyclin-dependent kinase activity.24 
Another method used quite commonly is one based 
on restoring the fluorescence of a quenched fluorophore. This approach has been seen in kinase 
as well as protease assays. In the latter, a self-quenching fluorophore must be placed at several 
residues on a peptide substrate in close proximity,25 or ones that come in close proximity due to 
secondary structure.26 Upon enzymatic cleavage of the peptide substrate, the local concentration 
Figure 1. Quench-based kinase assay dependent 
on the recruitment of a reader protein. 
Reproduced with permission from Wiley: 
ChemBioChem 2014, No. 15, 2298. 
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of the fluorophore decreases, and fluorescence intensity increases in turn. In kinase assays, 
quenching-based fluorescent assays can take multiple forms. Tyrosine and tryptophan, both 
viable phosphorylation sites, are known to quench a variety of organic fluorophores through π-π 
interactions.27,28 Phosphorylation can disrupt the stacking and result in a fluorescence 
enhancement (Figure 2). Alternatively, the Lawrence lab developed the “deep-quench” method, 
which they used to monitor PKA activity.29,30 In this construct, the fluorophore is quenched by a 
molecule in solution. Upon phosphorylation, the corresponding phospho-peptide binds to a 
phospho-recognition domain thereby effectively shielding the fluorophore from the quencher in 
solution and restoring fluorescence. In a more recently reported form of this biosensor, a 
positively charged fluorescent peptide was quenched by a negatively charged quencher. Upon 
phosphorylation, the quencher was released due to electrostatic repulsion, leading to increased 
fluorescence.31 
  
Figure 2. Quench-based kinase assay. The fluorophore is quenched by tyrosine, and upon phosphorylation, fluorescence is 
restored. Reproduced from Chem. Soc. Rev. 2012, 41 (5), 1652 with permission of The Royal Society of Chemistry. 
Förster resonance energy transfer (FRET) is perhaps one of the most common detection 
methods among all biosensors. A donor-acceptor pair conjugated onto opposite ends of a peptide 
substrate (within Förester radius), and upon enzymatic cleavage, the donor-acceptor pair are 
separated, leading to a detectable change in fluorescence (Figure 3). This FRET-quenching 
approach has been used to assay a multitude of proteases, including bacillus anthracis protease,32 
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MMP-9,33 and HIV protease.34 Apart from 
fluorescent dye molecules, much attraction has 
been paid to utilizing semiconductor quantum dots 
(QDs) to develop peptide-based FRET protease 
sensors.35 Particle size and surface modification 
control the absorbance and emission of QDs, 
allowing one to adjust them to match various 
fluorescent dyes. Several groups have successfully 
used QD-conjugated peptides to monitor the 
activity of various proteases, such as caspases,36 and Botulinum neurotoxin A.37 Impressively, 
QD-FRET methods are already being applied to microchip detection platforms, and are believed 
to have great potential for commercialization. 38 
All of the methods discussed above are based on monitoring changes in fluorescence. 
Another option is to pair fluorescence detection with a separation method, thereby observing the 
modified and un-modified peptide substrate simultaneously throughout an enzymatic reaction. 
The Allbritton group, in collaboration with the Lawrence group, reported the detection of several 
enzymes using capillary electrophoresis paired with laser induced fluorescence (CE-LIF). Using 
this technique, modified and un-modified peptide substrate are separated due to the difference in 
their electrophoretic mobility. They applied this method to monitoring the activity of several 
enzymes, including Abl,39 PKB,40 PKT,41 and PTP.42 This method can also be applied to 
monitoring protease activity, as the fragmentation products can be separated from the un-
degraded substrate, and even from each other.43,44 
Using peptides to monitor intracellular enzymatic activity 
Figure 3. FRET-based protease assay.166 
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While the number of peptide-based probes developed for in vitro detection of enzyme 
activity is vast, the examples of such probes used intracellularly are much fewer. Peptides are 
generally incompatible with the cytosolic environment, as they are rapidly metabolized by 
cytosolic peptidases.5 A limited number of aminopeptidases and endopeptidases are known to 
exist free in the cytosol of cells, including tripeptidylpeptidase II (TPPII),45–47 thimet 
oligopeptidase (TOP),48 prolyl oligopeptidase (POP),49 and leucine aminopeptidase (LAP).50,51 A 
common feature of these peptidases is a narrow cleft that contains the catalytic site, and evidence 
suggests that it is the N-terminus of peptides that initially enters the cleft.49,52–55 Several methods 
in the literature have taken advantage of these features to create longer-living peptides, for use as 
enzymatic reporters, as well as drug candidates.56 A few such approaches are discussed below. 
Note that this is a limited overview, and other notable methods (commonly used in the 
pharmaceutical industry), such as PEGylation57,58 and conjugation of macromolecules,59–61 will 
not be covered here. 
2.2.1. Peptidomimetics 
The incorporation of non-canonical amino acids or amino acid analogues into peptide 
regions important for enzymatic activity is expected to strongly affect their efficacy as substrates. 
This holds true with proteases as well. β and γ-amino acids, N-methylated amino acids, and even 
D-amino acids have been shown to increase a peptide’s resistance to proteolysis.62,63 For 
example, Hamamoto et al. demonstrated this in their development of a small antimicrobial 
peptide. Partial incorporation of D-amino acids made the peptide, though short and cationic, 
more resistant to trypsin degradation than its L-amino acids counterpart.64 Tugyi et al. also 
demonstrated that the stability of peptide immunogens was increased by incorporation of D-Thr 
and D-Pro at several sites.65 This has been further iterated in our lab, when a β-hairpin made of 
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all D-amino acids was found to remain completely intact even after 24 hours of incubation with 
pronase E, showing no degradation at all. However, an unstructured L-amino acid peptide 
attached to the C-terminus of the D-beta-hairpin was degraded rapidly, suggesting that D-amino 
acids do not prevent threading into the catalytic cleft of the enzymes.66  The use of β- and γ- 
amino acids was also found to successfully increase resistance in peptides. Separate work done 
by the Seebach  and Gellman labs showed peptides made entirely of β- and γ- amino acids are 
resistant to proteolysis by a number of different proteases.67–69 More significant modifications to 
the peptide backbone to enhance resistance are also seen in the literature, including ester 
linkages, peptoids, oligoureas, and azapeptides.57,70–72 
In order to use such peptides as enzymatic substrates, they must maintain the ability to be 
recognized by the target enzyme. One can infer that residues important for catalytic activity must 
therefore remain unmodified. Optimal results can be achieved by careful analysis of cleavage 
sites, followed by modifications at those sites alone. Proctor and co-workers used this approach 
to develop protease resistant peptide probes for kinase activity. After incubation of a peptide 
substrate in cytosolic lysate, the degradation products were analyzed using CE-LIF. Cleavage 
sites were identified and the residues substituted with non-native amino acids. Through an 
iterative design process, they were able to attain a 15-fold increase in the half-life of an Abl 
substrate peptide,39 and a 4.6-fold increase in a PKB substrate peptide, which was then used as a 
reporter to measure PKB activity in a single cell.40 In another example, Turner et al. showed that 
placing 7- (S)-hydroxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid (L- Htc) in the place of 
tyrosine in a PTK substrate peptide was enough to double the half-life in cell lysates, allowing it 
to be used as an intracellular reporter.41 Though effective, this method requires multiple rounds 
of iterative design for each peptide, which can be extremely time consuming and costly. 
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Additionally, each modification made to a peptide can also affect its efficacy as a substrate for 
the enzyme of interest, and so a delicate balance must be maintained. 
2.2.2. Secondary Structure 
Research has shown that well-folded peptides have longer lifetimes in cytosolic 
environments than those of their unstructured counterparts. This is believed to be due to the fact 
that in their folded form, peptides are too large to enter the narrow catalytic cleft of cytosolic 
proteases, thereby limiting their degradation. Work from our lab has shown evidence to that 
effect. A series of β-hairpins composed of entirely natural amino acids were synthesized and the 
rate of degradation in α-chemotrypsin, trypsin, and pronase E were measured. As was expected, 
a direct correlation between the fraction folded and the stability of a peptide was seen, reaching 
up to a 42-fold increase in half-life for the best folded β-hairpin.73 Taking advantage of this 
correlation, along with the evidence that cytosolic proteases thread peptides in through the N-
terminus,49,52–55 our group further showed that the inclusion of a small β-turn at the N-terminus 
of a linear peptide can extend its lifetime in cytosolic environment up to 10-fold.74 The protected 
peptide, a known Abl substrate, maintained its biological activity, and was successfully 
phosphorylated by the Abl kinase.74 
Cyclic peptides have also exhibited substantial resistance to proteolysis.75–78 Such peptides 
are bulky (preventing entrance to proteases’ catalytic cleft), lack an N-terminus (preventing 
recognition by aminopeptidases), and unlike β-hairpins, which sample both a folded and un-
folded form in solution, they are permanently locked in that conformation. Examples of that can 
be seen in nature; naturally occurring cyclic peptides such as Gramicidin and Polymyxin B are 
metabolically stable, allowing them to be used as therapeutic agents.79 Inspired by some of these 
natural products, the ability to impart that stability on synthetic peptides via cyclization has been 
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extensively investigated in the literature. In a paper published in 1996, Kyb et al. synthesized 
various cyclic analogues of Substance P (SP), a member of the tachykinin neuropeptide family, 
and studied the effect of cyclization on its properties. Cyclized peptides, though with varying 
biological activity, consistently showed increased metabolic stability, with up to 80% remaining 
after 2 hour incubation in parotid gland slices (compared to 50% of the linear peptide within 6 
minutes).80 In a more recent example, Hess et al. explored the effect of structural and 
conformational modifications on the intestinal permeability and metabolic stability of 
hydrophilic peptides. A library of 18 cyclic peptides was screened, and in all cases, cyclization 
dramatically reduced proteolysis by brush border enzymes.81 They carried out the same tests on a 
tetrapeptide derived from melanocyte-stimulating hormone (αMSH), a peptide with potential as a 
therapeutic agent for treating obesity. As in the prior case, they found that cyclized analogues all 
displayed improved metabolic stability.82  
Although cyclization remains the most effective way to protect peptides from proteolytic 
degradation, this method does not come without its challenges. Cyclization of peptides is not 
always feasible, whether it’s due to a lack of suitable side chain functionalities, or because of the 
importance of such functionality for bioactivity. Furthermore, the conformational constraints that 
help maintain metabolic stability can also render a peptide inactive, locking it in a conformation 
that is unfavorable for binding/catalysis.83 In collaboration with the Allbritton group, our group, 
in an extension of the work described above, cyclized the β-turns at the N-terminus of an Abl 
substrate peptide, thereby leaving the substrate region linear and the substrate efficacy un-
affected. This showed up to a 4-fold increase in lifetime over its non-cyclized counterpart (40-
fold increase over the linear peptide alone). This peptide was then used in an intracellular Abl 
kinase assay. This was not previously possible with the unprotected substrate, as it degraded too 
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quickly.74 However, even in this best case scenario, the synthesis of cyclized peptides is no 
trivial task, as is evident by the constant efforts to improve and develop new methods of 
cyclization.84 
3. Purpose of this work 
As is evident by the above discussion, despite the great advantages of using peptides as 
reporters, incorporating them into intracellular assays is challenging, as they get rapidly degraded 
by proteases. While some methods exist to prevent that, none go without affecting the 
efficacy/bioactivity of the peptide in question, and the most commonly used ones are also 
synthetically and/or financially draining. To further the use of these probes, a generalizable and 
synthetically simple method is needed to make them more stable in cytosolic environment. 
Described below is the work done to develop a technique for increasing the protease resistance 
of peptides, thereby allowing their effective use in intracellular enzymatic assays. A variety of 
protecting strategies were tested for their ability to prevent or slow down proteolytic degradation 
of a linear peptide. The most successful method was then applied to several different peptides, 
and their efficacy as enzymatic substrates was evaluated. One of the protected peptides was then 
carried forward to use as a substrate in an intracellular phosphorylation assay (Figure 4). 
 
Figure 4. Intracellular phosphorylation assay analyzed by CE-LIF using a fluorescent peptide substrate.  
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Chapter II. Design, Synthesis, and Characterization of Protected Peptides (Protectides) 
for Kinases 
 
1. Introduction 
To address the limitations in intracellular enzyme assays described in chapter one, we aimed 
to develop protected peptide substrates, which we call “protectides”. Our design focused on the 
three characteristics known to be common among cytosolic proteases: narrow catalytic cleft, 
highly charged surface area, and threading of peptides in an N- to C-terminus manner.49,52–55 We 
reasoned that entrance into the catalytic clefts can be prevented through sterics, by addition of 
bulky groups, or electrostatic repulsion, by incorporating negative charge into peptides, at the N-
terminus. To begin our work on developing a protection method, a peptide sequence on which to 
test protecting groups was needed. We envisioned ultimately using our protecting strategy on a 
peptide substrate in an enzymatic assay. It was therefore ideal to test possible protecting groups 
(termed “protectides”) directly on the substrate in mind. We decided to demonstrate our work on 
kinase substrates. Kinases are a superfamily of enzymes that are responsible for the 
phosphorylation of tyrosine, threonine, and serine. They play an important role in a large set of 
vital processes, including cell differentiation, gene expression, and apoptosis.85 The involvement 
of these enzymes in so many aspects of cell function makes cells extremely vulnerable to any 
alterations in their function, be it due to mutations, or overexpression. Dysregulation of kinases 
is in fact implicated in a wide range of diseases, including, but not limited to, diabetes, infectious 
disease, cardiovascular disorders, and cancer.86 Kinase inhibitors are currently among the most 
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heavily investigated drugs,87 motivating the development of robust probes for intracellular kinase 
assays. 
2. Analysis of an Unprotected Kinase Substrate 
Many peptide sequences are known to function as kinase substrates, and the choice of one for 
these purposes was rather arbitrary. We initially decided to use the sequence RKRDRLGTLGI-
NH2, reported by Kunkel et al. to be a selective PKB substrate.
88 The synthesis of this peptide, 
however, turned out to be quite problematic due to aspartamide formation, and the desired 
peptide was never isolated. This was quickly abandoned in favor of another PKB substrate 
peptide, GRPRAATFAEG-NH2, previously used by our collaborators in the Allbritton lab.
89 
This peptide was cleanly synthesized by hand or by an automated synthesizer, and despite the 
low overall charge, it did not present any solubility problems at the concentrations needed for 
this work. The control peptide 1 was simply capped with (5,6)-carboxyfluorescein ((5,6)-FAM) 
at the N-terminus for visualization (Figure 5) and served as the standard for comparison for all of 
the studies described below. 
 
Figure 5. Control peptide 1. The substrate is in black, and the fluorophore is shown in green. 
The stability of peptide 1 in the presence of cytosolic peptidases was tested by incubating in 
HeLa cell lysates at 37 °C. Aliquots were removed and quenched with equal amount of 
hydrochloric acid at various time points and the amount of intact peptide left was determined by 
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capillary electrophoresis paired with laser induced fluorescence (CE-LIF) (Figure 6). Based on 
peak integrations relative to an added internal standard ((5,6)-FAM), the half-life of the peptide, 
the point at which 50% remained un-degraded, was found to be 15±2 minutes.  
 
Figure 6. Electropherogram from a degradation assay of control peptide 1. 
Throughout the rest of this chapter, various protecting methods, or “protectides”, are 
evaluated. All protected peptides consist of the substrate sequence, shown in black, a PEG 
spacer, shown in red, a fluorophore conjugated to a lysine residue, shown in green, and a 
protecting moiety, shown in blue (Figure 7). All peptides, unless otherwise stated, were 
synthesized via standard Fmoc solid phase chemistry, and all were amidated at the C-terminus. 
Peptide characterization was done using HR ESI-MS or LC-MS. 
 
Figure 7. General design of peptide constructs. The PKB substrate is in black, the spacer in red, the lysine conjugated fluorophore 
in green, and the protecting group in blue. 
3. Beta-Hairpins as “Protectides” 
Previous work in our lab has shown that appending small β-turn structures to the N-terminus 
of a linear peptide can extend its lifetime in cytosolic environment, 74 presumably due to the 
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steric bulk preventing entrance into the narrow catalytic clefts of proteases. With this knowledge 
at hand, we set out to examine the effect of attaching more highly folded and “click-cyclized” β-
hairpins to the N-terminus of a substrate peptide to see whether longer half-lives were achievable 
with this method. Three peptide sequences known to fold well were adapted from the literature 
and modified for our purposes: Ac-WIpOOWTGPS (ACAP1), Ac-WVWVpOOKIWTG 
(ACAP2),90,91 and Ac-RK(N3)VKVpGOWIG(propargyl)Q (NHB).
92 ACAP1 and ACAP2 were 
designed by Andersen et al. with a unique capping motif that enhances folding and minimizes 
terminal fraying of β-hairpins. This capping motif, “acyl-W-loop-WTG”, confers additional 
stability through a face-to-edge Trp-Trp interaction, hydrogen 
bonding of the Thr residue with the N-terminal acyl group and 
the HN of Gly, and a CH-π interaction between the N-terminal 
Trp and C-terminal Gly (Figure 8).91 Since the incorporation of 
noncanonical amino acids is known to increase protease 
resistance,40,62 ornithines were incorporated in ACAP1 and 
ACAP2 at positions that were shown to be unimportant for 
folding. NHB, designed by Park and Waters, was shown to be amenable to cyclization via click 
reaction, and in its cyclized form, showed no degradation after 48 hours of incubation with 
Pronase E.92 We thus chose to investigate its effect, in both the cyclized and un-cyclized form, 
on the PKB substrate. The PKB substrate was synthesized with each one of these hairpins 
appended to its N-terminus (peptides 2-4, Figure 9) in a linear manner. The peptides’ half-lives 
in HeLa cytosolic lysate was then measured using CE-LIF for analysis. 
Figure 8. An example peptide 
highlighting the noncovalent 
interactions of the Andersen 
capping motif. 
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Figure 9. (A) Protected peptides 2-4. (B) Structure of peptide 2. The PKB substrate is in black, the PEG spacer in red, the lysine-
conjugated FAM in green, and the protecting β-hairpin in blue. 
When appended to a β-hairpin, up to a 3-fold increase in half-life relative to peptide 1 
was seen. Peptides 2 and 3 were within error of each other, with peptide 2 having a half-life of 
26±3 minutes, and peptide 3 30±5 minutes. Peptide 4, in its unclicked form, showed the greatest 
improvement over the control peptide, with a half-life of 45±7 minutes (Figure 10 & Table 1). 
Since cyclized peptides are known to dramatically improve metabolic stability,75–78 it was 
postulated that cyclization of peptide 4 would further enhance the lifetime of the protected 
substrate. Attempts at cyclizing peptide 4 (using the procedure outlined by Park & Waters92), 
however, proved futile, only further illustrating the impracticality of relying on peptide 
cyclization for protection. 
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Figure 10.Degradation of peptides 1-5 in HeLa cytosolic Lysate. Error bars represent the standard deviation from three trials. 
Table 1. Half-lives of peptides 1-5 in HeLa cytosolic lysates.a 
Peptide t1/2 (minutes) 
Peptide 1 15±1 
Peptide 2 26±3 
Peptide 3 30±5 
Peptide 4 45±7 
Peptide 5 25±2 
a Error was determined based on the standard deviation from three runs. 
 We chose to also test the effect of adding “protection” on the C-terminus of a peptide. 
Since the addition of another β-hairpin on the C-terminus of the peptide would have been far 
more synthetically challenging, we chose to take advantage of the negatively charged surface of 
cytosolic proteases,5,48 and hoped that the addition of negative residues to the C-terminus of the 
peptide would help by creating electrostatic repulsion between the peptide and the catalytic cleft 
of peptidases. This hypothesis was tested on peptide 3. We initially attempted to synthesize it 
with four glutamic acid residues added to the C-terminus. However, this peptide was never 
successfully isolated. Sequential reduction of the number of residues added was finally 
successful, as the peptide was made and isolated with two glutamic acids added (peptide 5, 
Figure 11). This additional modification of the C-terminus, however, did not appear to have an 
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effect on the peptide’s stability, as its half-life remained within error of peptide 3 (Figure 10 & 
Table 1). 
 
Figure 11. Peptide 5. Protected by a β-hairpin at the N-terminus and two glutamic acid residues at the C-terminus. 
4. Supramolecular “Protectide” 
In 2011, Urbach 
demonstrated the ability of a 
synthetic cucurbit[7]uril (CB[7]) 
to bind the 4-tert-butyl and 4-
amino-methyl derivatives of 
phenylalanine with sub-
micromolar dissociation constants (Kd). Binding was shown to be promoted by the positive 
cooperativity between the N-terminal ammonium group and the side chain ammonium group in 
the case of aminomethyl phenylalanine (Figure 12). Placement of these residues at the N-
terminus of tripeptides did not reduce the affinity, and in some cases even improved it due to 
additional cooperativity by the peptide backbone.93 In 2013, Urbach et al. reported the use of 
CB[7] to inhibit the degradation of a peptide by aminopeptidase N (APN), a non-specific 
exopeptidase. In the presence of CB[7], digestion of a peptide stopped upon reaching a Phe or (4-
aminomethyl)Phe residue, and the remaining peptide was stable for at least 24 hours (Figure 13). 
Figure 12. Binding of Urbach’s Cucurbit[7]uril to various phenylalanine 
derivatives. Reprinted with permission from J. Am. Chem. Soc. 2011, 133 
(42), 17087. Copyright 2011 American Chemical Society. 
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The extent of protection of an N-terminal residue was found to directly correlate to its binding 
affinity to CB[7].94 This study, however was done in the presence of a single, purified peptidase. 
We decided to see if this approach could be extended 
to multiple peptidases, such as those in the cytosol of a 
cell. Based on the above results, we speculated that 
placement of a Phe or (4-aminomethyl)Phe residue at 
the N-terminus of our peptide substrate could inhibit 
degradation by aminopeptidases. Since (4-
aminomethyl)Phe is known to have a higher affinity 
towards CB[7],93,94 we chose to test this hypothesis by 
appending it to the N-terminus of our peptide. 
Attempts were made to synthesize the peptide with a 
free N-terminus to get maximal binding (Kd~1.88 nM),
94 but the peptide was never successfully 
isolated, or even detected in crude mixtures. We instead used the Ac-capped peptide (peptide 6, 
Figure 14), as CB[7] displays strong binding to peptides containing (4-aminomethyl)Phe as an 
internal residue as well (Kd~510 nM).
93 
 
Figure 14. Peptide 6. 
Figure 13. Schematic illustration of the 
inhibition of APN-mediated peptide digestion 
at a Phe residue using CB[7]. Reprinted with 
permission from J. Am. Chem. Soc. 2013, 135 
(31), 11414. Copyright 2013 American 
Chemical Society. 
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The stability of peptide 6 was assessed with and without CB[7] (commercially available) in 
the same manner described above, using CE-LIF for analysis. In the absence of CB[7], the 
peptide was found to be 50% degraded within 5±0.4 minutes. In the presence of 2-fold excess of 
CB[7] (20 µM), the half-life of the peptide was 20±1 minutes, representing a 4-fold increase 
(Figure 15). It is possible that while the cucurbituril is large enough to block entrance into the 
catalytic cleft of the peptidase APN, it is not large enough to do so for some other peptidases 
found in the cytosol, as size differences do exist. Additionally, despite the strong binding 
affinity, it is still a reversible process, just like the folding of β-hairpins, and the peptide could 
thread into the proteolytic cleft while sampling the off state.  While the concentrations used were 
well above the reported Kd, it is important to note that these assays were carried out in PBS, and 
not in ammonium phosphate buffer as was reported in the literature.94 The difference in buffer, 
and especially the presence of such high concentrations of salts (and of course everything else 
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present in cell lysates), could have a profound effect on the binding properties of CB[7], though 
this was not investigated further. 
 
Figure 15. Degradation of peptide 6, with and without CB[7], in HeLa cytosolic lysates. Error bars represent the standard 
deviation of three runs. 
 
5. Aryl Cap as “Protectide” 
With the above results at hand, it was deemed best to move away from using reversible 
processes for protection and focus on covalent attachment of protecting groups. In another article 
published by Urbach and Ramalingam, they outlined the synthesis of 2 rotaxanes, each comprising a 
viologen core threaded through a similar, this time cucurbit[8]uril macrocycle (CB[8]), and 
stoppered by tetraphenylmethane groups (Figure 16).95 Since the tetraphenylmethane unit is large 
enough to stopper the rotaxane, it was our hope that it would be large enough to act as a barrier 
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Figure 16. Urbach’s rotaxane, stoppered by tetraphenylmethane groups. Reprinted with permission from Org. Lett. 2011, 13 
(18), 4898. Copyright 2011 American Chemical Society. 
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to sterically restrict access of our substrates into the catalytic cleft of cytosolic peptidases, 
thereby increasing the lifetime of the peptide substrates. Based on structural analysis of several 
peptidases found in the cytosol, the tetraphenylmethane is larger than the entrance to the catalytic 
site in some. Thus with its large size, unnatural structure, and unnatural linker to the peptide, we 
hypothesized that is could hinder the recognition of the peptidic substrate by the peptidase, 
thereby reducing threading into the catalytic cleft and extending its lifetime. 
To test this hypothesis, a tetraphenylmethane unit was appended to the N-terminus of the 
peptide substrate via a click reaction. Since FAM in itself is an unnatural component of this 
peptide, its possible role was tested by synthesizing two versions of the protected substrate: one 
in which the lysine conjugated FAM was on the N-terminal side (peptide 7), and one in which it 
was on the C-terminus (peptide 8). Since the peptide substrate has an overall charge of only +1, 
the addition of a large hydrophobic aryl cap was expected to cause solubility problems. To 
circumvent that, ornithines were incorporated at the N- and C-terminus of the peptide substrate, 
separated from it by a glycine residue (Figure 17). 
 
Figure 17. Peptides 7 and 8. 
Synthesis  
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The tetraphenylmethane stopper (aka the aryl cap) was synthesized in one step from 
commercially available 4-tritylphenol by treatment with propargyl bromide and K2CO3 (Scheme 
1) and characterized by 1H NMR. Attempts were made to synthesize a sulfonated protectide as 
well, in hope of getting greater protection due to charge repulsion, but attempts at sulfonation of 
the aryl cap led to inseparable product mixtures, the analysis of which (via 1H NMR and LC-MS) 
was always inconclusive. This approach was therefore abandoned. The azido-PEG2-acid linker 
was synthesized from cheap, commercially available diethylene glycol, starting with a high-
yielding desymmetrization using tBu-acrylate and sodium metal. The alcohol was then converted 
into an azide using DPPA and DBU, and the tBu-ester was deprotected in 1:1 TFA:DCM to 
reveal the carboxylic acid, which was then characterized by 1H NMR and ESI-MS (Scheme 1). 
 
Scheme 1. Synthesis of aryl cap and azido-PEG2-acid linker. 
 Synthesis of peptides 7 and 8 was carried out entirely on resin, using standard solid phase 
peptide synthesis up until the final step, in which the aryl cap was attached via an overnight solid 
phase click reaction, followed by cleavage and purification by standard methods. 
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Determination of proteolytic stability 
The proteolytic stability of peptides 7 and 8 was tested in HeLa cell lysates, and the results 
were analyzed using analytical RP-HPLC (Figure 18). Surprisingly, peptides 7 and 8 both 
displayed half-lives shorter than that of the control peptide 1, with t1/2 of ~7 minutes and ~5 
mins. For peptide 7 and peptide 8, respectively. This most likely reflects a more active batch of 
cell lysates, as peptide 1 was not run in parallel with this particular batch The placement of FAM 
did not appear to make a difference in their half-lives, though it is worth noting that peptide 8 
was completely degraded after 45 minutes, while trace amounts of peptide 7 were still seen after 
an hour. 
 
Figure 18. RP-HPLC traces following the degradation of peptides 7 & 8 in HeLa cytosolic lysates. 
New versions of the protected substrate were synthesized (in the same way as above) with a 
few changes in hopes of increasing resistance: FAM was incorporated on both the N and C 
terminus (peptide 9), the ornithines on the ends were replaced with three glutamic acids on each 
side to induce electrostatic repulsion (peptide 10), or both (peptide 11). In all three cases, a linker 
that is 2 PEG units long was used (Figure 19). With all three, however, trouble was encountered 
when trying to characterize the product. None of the products collected ionized by ESI-MS or 
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MALDI, and when run on the LC-MS, the only peaks seen were eluted off the column very 
quickly. 
 
Figure 19. Peptides 9-11. 
6. Dendrimers as “Protectides” 
As an extension of the steric blocking approach described above with the tetraphenylmethane 
group, the use of dendrimers as a capping motif was investigated as a protecting method. 
Dendrimers can be synthesized quite easily, making them practical to use. Their size can be 
systematically increased, with every generation synthesized, until a sufficient size is reached to 
effectively protect the peptides. Furthermore, their synthesis allows for the incorporation of 
multiple negative charges at the periphery, which may further help with protection due to the 
charge repulsion between them and the proteolytic cleft.49,54,55 This can also provide sites for the 
conjugation of cell-penetrable ligands when applied intracellularly. To that end, benzyl hydroxy-
dendrimers were synthesized, beginning from commercially available methyl 4-
methylbromobenzoate and 3,5-dihydroxybenzyl alcohol, following a standard literature 
protocol.96 Before final hydrolysis of the methyl esters on the periphery (once the desired 
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generation is reached), the benzylic alcohol at the focal point was converted to an azide to enable 
conjugation to the peptide via a click reaction (Scheme 2). The synthesis was high yielding for 
all the generations synthesized.
 
Scheme 2. Synthesis of azido-dendrimers. 
 Modeling suggested that the second generation ([G2]), third generation ([G3]), and fourth 
generation ([G4]) dendrimers would be in the size range necessary to restrict access into the 
clefts of cytosolic proteases (based on the crystal structure data available to date).49,52–55,97 
Dendrimers (HO2C)4-[G2]-N3 and (HO2C)8-[G3]-N3 (see Scheme 2 for naming) were 
synthesized. (HO2C)4-[G2]-N3 and (HO2C)8-[G3]-N3 were then clicked onto a purified propargyl 
glycine that was incorporated at the N-terminus of the substrate peptide to give the protected 
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peptides 12 and 13, respectively. The reaction was done in 10 mM phosphate buffer (pH 8) using 
a synthesized tris-tri(methylazolyl)amine ligand (Scheme 3). 
 
Scheme 3. Synthesis of dendrimer protected peptides via click reaction. 
 When tested for protease stability, peptide 12 showed a half-life of 35±7 minutes, an 
improvement over the unprotected peptide 1. It was expected that peptide 13 would show an 
even greater increase in half-life as the size of the dendrimer increases. However, attempts at 
analyzing the results of the degradation assay using both analytical RP-HPLC and CE-LIF 
proved unsuccessful, as almost no signal was seen. This quench in fluorescence is most likely 
due to the high local concentration of acid present in the periphery of the later generation 
dendrimers. Later generation dendrimers were thus not pursued as protectides. 
7. Dimerization as the Protection Strategy 
All of the approaches taken thus far relied on adding bulk to the N-terminus of a peptide in 
order to block its entrance to the catalytic cleft of cytosolic peptidases. We decided to take a step 
back and focus merely on masking the N-terminus to hinder recognition without relying on 
sterics. In considering straight-forward synthetic approaches to masking the N-terminus, we 
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hypothesized that N-terminal dimerization of a peptide could mask its N-terminus in the same 
way that cyclization would, but without the synthetic challenges or added conformational 
constraints that can often decrease substrate efficacy. Unlike N-terminal bulk, it will not add un-
necessary cargo that could bring about unforeseen changes in the peptide’s properties and 
activity. The idea of peptide dimers was brought about by recent work reported by Kier and 
Andersen. In a comprehensive study on the effect of various capping motifs on the folding 
properties of β-hairpins, Kier et al. introduced dicarboxylate capping motifs, among others, 
leading to the capping of two β-hairpins with one shared cap, thereby forming dimeric adducts. 
This was synthetically very simple, requiring just 1 equivalent of a dicarboxylic acid coupled 
during solid-phase peptide synthesis like any other amino acid.90 We adapted this method to 
create a dimer of the PKB substrate using succinic acid as the linker (peptide 14). This followed 
the same general structure of all other protected peptides, with the addition of a glycine spacer 
between K(FAM) and the dicarboxylate linker (Figure 20). 
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Figure 20. Peptide 14. 
The synthesis of the peptide dimer was successful on the automated synthesizer, on the 
microwave synthesizer, and by hand. Optimal results were achieved when the substrate sequence 
was synthesized on the automated synthesizer and all proceeding steps were done by hand. 
Dimerization proceeded efficiently, and the dimer was the major product of the reaction, 
according to LC/MS peak integration. Some succinic acid coupled to only one peptide was seen 
as well, and no peptide was seen that remained uncoupled. Despite the reported purity of the 
purchased carboxy-PEG3-amine (reported to be 99.5% pure), significant amounts of dimers with 
differing (longer) lengths of PEG chains were observed by ESI-MS, even after multiple rounds 
of purification by RP-HPLC. We hypothesized that a longer PEG chain may make dimerization 
more favorable, but since the PEG3 dimer remained the major product and the 1-2 unit change in 
the length of the PEG chain was not expected to have a significant effect on stability, we 
continued with the mixture for preliminary investigations. CE-LIF analysis of time points from a 
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degradation assay revealed a half-life of 420±24 minutes, a 28-fold increase over peptide 1. Such 
an improvement in stability has not been seen before outside the realm of cyclized peptides. To 
confirm that these results do not reflect co-elution of the parent peptide and fragments, CE-MS 
was used to analyze the samples (done by Mac Gilliland; Ramsey lab). Based on integration of 
the peaks relative to an added internal standard, the half-life of peptide 1 was 5 minutes, while 
the half-life of peptide 14 was 2 hours (Figure 21), representing the same fold increase seen by 
CE-LIF. 
.  
Figure 21. Degradation of peptides 1 & 14 as analyzed by CE-MS. *analysis done by Mac Gilliland in the Ramsey lab. Error bars 
represent the standard deviation of three runs. 
Extension 
7.1.1. Linker effect 
To test the role of the linker, two additional versions of peptide 14 were synthesized, one 
using isophthalic acid (peptide 15) and one using terephthalic acid (peptide 16) as the linker 
(Figure 22). We were particularly interested to see if the rigidity of the linker will have any effect 
on the stability of the peptide dimer. When tested against peptide 14, however, peptides 15 & 16 
appeared to have half-lives within error of peptide 14 (Figure 23), indicating the linker used does 
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not affect the degradation resistance. This can be seen as advantageous, potentially allowing for 
the incorporation of dyes or conjugation sites in the linker, for example.  
 
      Figure 22. Peptides 15 & 16. 
 
          Figure 23. Degradation of peptides 14-16 in HeLa cytosolic lysates. Error bars represent standard 
deviation of three runs. 
7.1.2. Substrate scope 
To evaluate the generality of this approach, we applied it to other kinase substrates. Dimers 
of a known PKC substrate (QKRPSQRSKYL-NH2)
98 and Abl substrate (EAIYAAPFAKKK-
NH2)
99 were synthesized, using succinic acid as the linker. The Abl dimer (peptide 19) was 
synthesized with a PEG4 linker. As we predicted, no dimers other than the desired one were 
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observed. The PKC dimer (peptide 20) was already synthesized with PEG3, so the mixture was 
used. A standard for comparison in which the N-terminus of the substrate sequence was simply 
capped with FAM was also synthesized for each substrate (Peptides 17 & 18, Figure 24). 
               
                        Figure 24. (A) Peptide standards 17-18. (B) Peptide dimers 19-20. *Peptide 19 was synthesized with a PEG4 linker. 
Analysis of peptide degradation showed an improvement with all peptides upon dimerization, 
with a 24-fold and 7.5-fold increase for the Abl and PKC substrates, respectively (Figure 25 & 
  Table 2). 
 
Figure 25. Degradation of control peptides 1, 17, & 18 and dimerized peptides 14, 19, & 20 in HeLa cytosolic 
lysate. Error bars represent the standard deviation of three runs. 
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  Table 2. Half-lives of peptides in HeLa cell lysates.a 
Peptide Standards t1/2 (mins) Peptide Dimer t1/2 (mins) Fold Increase 
Peptide 1 15±1 Peptide 14 420±24 28 
Peptide 17 5±1 Peptide 19 120±5 24 
Peptide 18 2±0.2 Peptide 20 15±3 7.5 
 a Errors are from the standard deviation of three runs. 
Substrate Efficacy 
7.2.1. In vitro Phosphorylation 
To assess the ability of the dimerized peptides to act as substrates for their respective 
enzymes, all peptides were synthesized using only one isomer of FAM ((5)-FAM) and a PEG4 
chain (herein indicated with * by the peptide number) in order to simplify analysis, since dimers 
with differing lengths of PEG chains (and even the 5- and 6- isomers of FAM) can be separated 
by CE, complicating the analysis. The peptides were incubated with purified kinase at 30 °C and 
phosphorylation was monitored over time using CE-LIF (Figure 26A&B). The identification of 
phosphorylated peaks was confirmed by HR ESI-MS. All dimer peptides were phosphorylated 
by their respective kinase, on one or both of the phosphorylation sites, indicating that the 
dimerization did not hinder the peptide’s ability to act as a substrate. Dimers were 
phosphorylated to a similar extent as their un-dimerized counterpart, suggesting the rate of 
phosphorylation was not significantly perturbed (Table 3). Separation could not be achieved with 
peptide 20*, so phosphorylation could not be quantified. However, new peaks were clearly seen 
growing in (compared to the negative control) (Figure 26C&D) and HR ESI-MS confirms 
phosphorylation was taking place. 
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Figure 26. Electropherograms following the in vitro phosphorylation of peptides 17* (A) and 19* (B). Time 
points were taken at t=0, 1, 3, 5, 10, 15, & 20 minutes. (C) & (D) are Electropherograms following the in vitro 
phosphorylation of peptide 20*. Complete separation was never achieved. 
Table 3. Extent of in vitro phosphorylation of peptides 1*, 14*, & 17*-20* after 20 minutes. Ϯ Full separation could not 
be achieved, and phosphorylation was not quantified.a 
Peptide Standard % Phosphorylated Peptide Dimer % Phosphorylated 
Peptide 1* 27±2 Peptide 14* 30±2 
Peptide 17* 17±2 Peptide 19* 16±1 
Peptide 18* 42±6 Peptide 20* ------ 
      a Error represents the standard deviation of three runs 
7.2.2. Phosphorylation in Cell Lysates 
Since previous work in our lab has been done on increasing the lifetime of peptide 17, we 
chose to move forward with peptides 17* & 19* for comparison. The phosphorylation of peptide 
19* in a cytosolic lysate was tested. Peptides 17* & 19* were incubated at 30°C in Baf/BCR-Abl 
cytosolic lysate containing ATP and a cocktail of phosphatase and protease inhibitors, and 
phosphorylation was monitored using CE-LIF (Figure 27). Both peptides 17* & 19* were 
phosphorylated over time at comparable rates: peptide 17* was 87±2% phosphorylated after 2 
hours, and peptide 19* was 86±0.1% phosphorylated relative to non-degraded peptide (due to the 
overlay, peaks for peptide 19* were de-convoluted as described previously44 using Origin 9.0. 
The error reported for the calculated peak area was 3-9%). 
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Figure 27. Electropherograms monitoring the phosphorylation of peptides 17* (A & B) and peptide 19* (C & D) in 
Baf/BCR-Abl cytosolic lysates. Time points were taken at (top to bottom) t=1, 1.5, & 2 hours. (A) & (C) are the negative 
controls in which no ATP was added. 
7.2.3. Phosphorylation in Living Cells 
The performance of peptide 19* intracellularly was then assessed. Peptide 17* or 19* were 
pinocytosed, along with sodium pervanadate as phosphatase inhibitor, into live Baf/BCR-Abl 
cells and incubated at 37°C for 25 minutes. It is worth noting that pinocytosis puts a significant 
amount of stress on cells, making it an even more hostile environment for peptides. The cells 
were then lysed and the cellular contents analyzed by CE-LIF (Figure 28). Peptide 17* seemed to 
have completely degraded, as no intact phosphorylated or un-phosphorylated peptide was seen. 
Peptide 19*, however, did not exhibit complete degradation, and both un-phosphorylated and di-
phosphorylated peptide were seen. The peptide dimer was 54±8% phosphorylated relative to 
intact peptide remaining, and together, those constituted 19±2% of all species present. 
Interestingly, unlike with the in vitro assays, no mono-phosphorylated peptide was detected. This 
could be due to the more crowded environment within a cell, making a second phosphorylation 
event on the same peptide more favorable than the mono-phosphorylation of another substrate 
due to proximity. 
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Figure 28. Electropherograms measuring the amount of peptide 17* (B) and 19* (D) phosphorylated in Baf/BCR-Abl 
cells after 25 minutes of incubation. (A) and (C) show time points from in in vitro assays of peptide 17* and 19*, 
respectively, for comparison of migration times. 
8. Conclusions 
A variety of N-terminal capping motifs were tested for their ability to impart protease 
resistance on a PKB substrate peptide (results summarized in Table 4). Like most approaches 
that increase steric bulk, the ones examined here appeared to have only a minor influence, 
suggesting that steric hindrance alone is not effective. With all of the attempted steric caps, it is 
important to remember that the inhibition of digestion by cytosolic proteases could be the result 
of disruption of binding necessary for catalysis within the cleft, and not due to an inability to 
enter it. In that case, it stands to reason that endopeptidases would not be affected by the N-
terminal steric cap protection approach, which could explain why only a limited increase in half-
lives was seen. 
Table 4. Half-lives of peptides in HeLa cytosolic lysates.a 
 Peptide t1/2 (minutes) 
PKB Substrate Std Peptide 1 15±1 
Beta-hairpins Peptide 2 26±3 
 Peptide 3 30±5 
 Peptide 4 45±7 
 Peptide 5 25±2 
Supramolecular Peptide 6 5±0.4 
 Peptide 6+CB[7] 20±1 
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Aryl Cap Peptide 7 ~7 
 Peptide 8 ~5 
Dendritic Peptide 12 35±7 
a Error was determined based on the standard deviation from three runs. 
Of all the methods tested, the most successful was one that entirely neglected the idea of 
adding bulk for steric hindrance. Skewing proteases’ ability to recognize the N-terminus of 
peptides via their dimerization effectively increased the half-life of peptides by up to 28-fold, 
leading to half-lives on the hour time scale in HeLa cytosolic lysates. This method is 
synthetically far simpler than peptide cyclization, the only method previously shown to impart 
this level of resistance, and did not affect their efficacy as substrates for their respective kinases. 
The use of this protection strategy in intracellular assays was demonstrated using peptide 19* in 
Baf/Bcr-Abl cells, in which phosphorylation of the peptide was observed and successfully 
quantified via CE-LIF. This strategy is expected to further promote the use of peptide reporters 
for the study of intra-cellular enzymatic activity, in both healthy and diseased cells, generating 
further knowledge of their correlation to various disease states, potential therapeutics, and even 
monitoring disease progression and effectiveness of various therapies in patients. 
9. Experimental 
Synthesis of Peptide Substrates 
Peptides were synthesized using manual or automated standard solid phase peptide synthesis 
(Thuramed Peptide Synthesizer, CEM Liberty 1 Microwave Peptide Synthesizer) using Fmoc 
protected amino acids on 0.057-0.25 mmol of RINK Amide resin. Four equivalents of standard 
amino acids were used for each peptide coupling while 2 equivalents of orthogonally protected 
lysine (for attachment of FAM) and PEG derivatives and 1 equivalent of dicarboxylic acid 
dimerization linkers were used. The sidechains of orthogonally protected lysine were protected 
with 1-(4,4-dimethyl-2,6- dioxocyclohex-1-ylidene-3-methylbutyl (N-ivDde) or 
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allyloxycarbonyl (N-alloc). Specific deprotection protocols are outlined below. (5)-FAM or 
(5,6)-FAM was coupled to the ε-NH of lysine or the N-terminal using 4 equivalents of FAM, 5 
equivalents of PyBOP/HOBt and 8 equivalents of DIPEA in DMF and allowed to bubble with N2 
overnight. Coupling of FAM to a peptide was always the last step done on resin. 
 
Peptides were cleaved from the resin in 9.5:2.5:2.5 trifluoroacetic acid (TFA), TIPS and water 
respectively for 3-4 hours. The TFA was evaporated and the cleaved peptides were precipitated 
using cold ethyl ether and extracted with water. Extracted peptides were lyophilized and then 
purified using semi-preparative RP-HPLC on a Vydac C18 semipreparative column with a 
gradient from ‘0 to 100% B’ in 45-120 minutes. Solvent A was 95% H2O, 5% CH3CN and 0.1% 
TFA and Solvent B was made of 95% CH3CN, 5% H2O and 0.1% TFA. Second and third round 
of purification of peptide dimers was done with the column heated to 45°C. For purification of 
dendrimer conjugated peptides, a buffered mobile phase was used where solvent A was 10mM 
NH4OAc in H2O and solvent B was 10 mM NH4OAc in 10% H2O, 90% CH3CN. Purified 
peptides were lyophilized and their purity confirmed by Analytical LC/MS on an Agilent Rapid 
Resolution LC-MSD system, equipped with an online degasser, binary pump, autosampler, 
heated column compartment, and diode array detector. Dendrimer conjugated peptides were 
dissolved in 10-11% NH4OH/H2O and characterized using HR ESI-MS. 
Synthesis of Peptide Dimers 
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Substrate peptides were synthesized on 0.25 mmol RINK amide resin using standard Fmoc 
coupling. All proceeding couplings were done using the same conditions (unless otherwise 
noted) with differing equivalents of acid. Fmoc-protected PEG amino acid was then coupled 
using 2 equivalents for 4 hours, followed by Fmoc-Lys-ivDde using 2 equivalents for 4 hours, 
and then Fmoc-Gly using standard coupling conditions. After deprotection, succinic acid was 
coupled using 1 equivalent overnight for dimerization. Finally, the ivDde group was removed 
using 2% hydrazine-monohydrate in DMF (3 x 5 minutes), and FAM was coupled on using 4 
equivalents of FAM, 5 equivalents of PyBOP/HOBt and 8 equivalents of DIPEA in DMF 
overnight. 
On-Resin Click 
Cu(II)SO4•5H2O (3.5 eq.) and Na-Ascorbate (3.5 eq.) were mixed in DMF and let stir for 30 
minutes. The alkyne moiety (3.5 eq.) was then added to the mixture and let stir for an additional 
30 minutes. The mixture was then added to the resin, followed by the addition of DIPEA 
(1µL/µmol resin loading). The reaction was agitated over-night, washed with DMF and DCM, 
and followed by the deprotection of a lysine as outlined below. 
Alloc Deprotection 
Alloc deprotections were carried out in 1:2 DCM:ACN in the presence of Pd(OAc)2 (0.3 eq.), 
PPh3 (1.5 eq.), NMM (10 eq.), and PhSiH3 (10 eq.). Care was taken to ensure the PhSiH3 was the 
last reagent added. The reaction was agitated over-night. After draining the solution, the resin 
was washed with THF (1 x 5mL x 5mins.), DMF (2 x 5 mL x 2 mins.), sodium 
diethyldithiocarbamate trihydrate solution (25 mg/ 1 mL DMF) (4-5 x 5 mL x 10 mins.), DMF (2 
x 5 mL x 2 mins.), and DCM (2 x 5 mL x 5 mins.). *This series of washes was used following 
any reaction that used palladium. 
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ivDde Deprotection 
The removal of ivDde from the sidechain of lysine was accomplished by treating the peptide 
resin 3 x 2 mins with 20 mL of 2% hydrazine monohydrate in DMF bubbling with N2 followed 
by washing with DMF and DCM. 
Synthesis of aryl cap 
 
Synthesized as previously reported in literature.100 
Synthesis of azido-PEG2-acid 
 
Synthesized as previously reported in literature.101 
Synthesis of benzyl hydroxy-dendrimers 
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Synthesized as previously reported in literature.96 
Synthesis of azido-dendrimers 
 
The benzyl hydroxyl-dendrimer (1.54 mmol) was dissolved in 4:1 toluene:DMF (25 mL). DPPA 
(3.94 mmol) and DBU (3.68 mmol) were added and the solution was let stir at 70 °C over-night. 
The resulting mixture was concentrated in vacuo, taken up in EtOAc, and washed with water. 
The solution was then dried over MgSO4, and concentrated in vacuo to yield a dark brown 
sludge. The product was purified by column chromatography in 0%  10% ether/DCM gradient 
to yield the product as a white solid. 
(MeO2C)4-[G2]-N3 (1.5449 g, 92.0% yield): 
1H NMR (CDCl3) δ 8.06 (d, 8H), 7.49 (d,8H), 6.68 
(s, 4H), 6.56 (s, 2H), 6.53 (s, 3H), 5.12 (s, 8H), 4.99 (s, 4H), 4.27 (s, 2H), 3.94 (s, 12H). 
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(MeO2C)8-[G3]-N3 (0.7338 g, 73.1% yield): 
1H NMR (CDCl3) δ 8.04 (d, 16H), 7.47 (d,16H), 
6.67 (s, 8H), 6.65 (s, 4H), 6.55 (m, 9H), 5.08 (s, 16H), 4.97 (s, 12H), 4.25 (s, 2H), 3.92 (s, 24H). 
 
Final hydrolysis of the esters was carried out as previously reported in literature.96 
(HO2C)4-[G2]-N3 (0.9883 g, 89.8% yield): 
1H NMR (MeOD) δ 8.00 (d, 8H), 7.98 (d,8H), 6.65 
(s, 4H), 6.57 (s, 2H), 6.51 (s, 2H), 6.47 (s, 1H) 5.08 (s, 8H), 4.98 (s, 4H), 4.22 (s, 2H). 
(HO2C)8-[G3]-N3 (0.6943 g, 83.7% yield): 
1H NMR (MeOD) δ 7.86 (d, 16H), 7.25 (d,16H), 
6.46 (s, 8H), 6.41 (s, 4H), 6.36 (s, 4H), 6.30 (s, 2H), 6.27 (s, 2H), 6.21 (s, 1H), 4.70 (s, 16H), 
4.56 (s, 12H), 2.68 (s, 2H). 
Synthesis of Tris-tri(methylazolyl)amine Ligand 
Synthesized as previously reported in literature92 
Solution Phase Click Reaction of Dendrimers 
Excess of azide (8.13 µmol) was added to a 1 mM solution of propargyl peptide (0.193 µmol) in 
10 mM phosphate buffer (pH 8). A pre-mixed solution of tris-tri(methylazolyl)amine (6.0 µmol) 
and [Cu(CH3CN)4][PF6] (4.0 µmol) in CH3CN (200 µL) (previously stirred for one hour) was 
added, followed by sodium ascorbate (5.0 µmol) in minimal amount of buffer. The solution was 
stirred over-night in the dark. The reaction was quenched by addition of 0.1% TFA in 95% H2O, 
5% CH3CN and lyophilized down to a solid. Products were then purified by RP-HPLC as 
described above. 
Cell Culture 
HeLa and Baf/Bcr-Abl cells were obtained from the American Type Culture Collection and 
cultured in DMEM medium supplemented with 10% FBS, penicillin (100 units/mL) and 
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streptomycin (100 µg/mL). All cells were maintained in a humidified atmosphere of 37 °C in 5% 
CO2. 
Degradation Assays 
A HeLa cell pellet was washed with and resuspended in phosphate buffered saline (PBS; 137 
mM NaCl, 10 mM Na2HPO4, 27 mM KCl, 1.75 mM KH2PO4, pH 7.4). The cells were 
submerged in liquid nitrogen for 1 min and rapidly thawed at 37 °C for a total of three cycles. 
The mixture was centrifuged at 14,000 x g for 15 min at 4 °C. The supernatant was transferred to 
a clean centrifuge tube and maintained on ice until use in the assay. Total protein in the lysate 
was determined by Bradford assay. 
Assessment of peptide degradation was performed by incubating peptide (10 µM) with the HeLa 
cell lysate (3 mg/mL total cell protein) at 37 °C. Aliquots were removed over time and quenched 
by addition of HCl to a final concentration of 100 mM. Samples were diluted 20-50x in 
electrophoretic buffer prior to analysis by CE-LIF (see below for methods and conditions), or 
analyzed by analytical RP-HPLC without any prior dilution with a gradient from ‘0 to 100% B’ 
in 25 minutes. Solvent A was 95% H2O, 5% CH3CN and 0.1% TFA and Solvent B was made of 
95% CH3CN, 5% H2O and 0.1% TFA. 
PKB Kinase Assay 
PKB Kinase assays were performed by incubating peptide (0.75 µM peptide 1* or 0.375 µM 
peptide 14*) with PKB-α (ThermoFisher Scientific; Waltham, MA) (0.125 ng/µL) in assay 
buffer [8 mM MOPS (pH 7.5), 0.2 mM EDTA, 4 mM MgCl2, and 1 mM ATP] at 30 °C. 
Aliquots were removed over time and quenched by heating to 95°C for 4 minutes. Samples were 
diluted 20-50x in electrophoretic buffer prior to analysis by CE-LIF. 
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Abl Kinase Assay 
Abl Kinase assays were performed as described above using 2.5 µM peptide 17* or 1.25 µM 
peptide 19* and 0.75 ng/µ Abl-1 (ThermoFisher Scientific; Waltham, MA) in assay buffer [50 
mM Tris (pH 7.5), 1 mM MnCl2, 5 mM MgCl2, 2 mM DTT, and 1 mM ATP]. 
PKC Kinase Assay 
PKC Kinase assays were performed as described above using 2.5 µM peptide 18* or1.25 µM 
peptide 20* and 5 ng/µL PKC-α (ThermoFisher Scientific; Waltham, MA) in assay buffer [20 
mM MOPS (pH 7.2), 1 mM DTT, 1 mM CaCl2, 10 mM MgCl2, lipid activator, and 1 mM ATP]. 
Lysate Phosphorylation Assays 
A Baf/BCR-Abl pellet was washed 2x with PBS buffer. The pellet was resuspended with 
Mammalian Protein Extraction Reagent (M-PER) with 1 mM sodium pervanadate and 1X 
Complete EDTA-Free Mini-TAB protease inhibitor cocktail (Roche) and vortexed for 10 
minutes. The mixture was then centrifuged at 14,000 x g at 4 °C for 15 minutes, and the 
supernatant was reserved and kept on ice until use. Total protein concentration was determined 
by Bradford Assay. 
Assessment of peptide phosphorylation was performed by mixing peptide (5 µM for peptide 17*, 
2.5 µM for peptide 19*) with Baf/BCR-Abl cell lysate (3 mg/mL total cell protein) in assay 
buffer [50 mM Tris (pH 7.5), 1 mM MnCl2, 5 mM MgCl2, 2 mM DTT, and 1 mM ATP]. And 
incubating at 30 °C. Aliquots were removed and quenched by addition of HCl to a final 
concentration of 100 mM. Samples were diluted 20-100x in electrophoretic buffer prior to 
analysis by CE-LIF. 
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Intracellular Phosphorylation Assays 
Approximately 5 million cells were isolated in a 1.5 mL tube and loaded with peptide 17* or 
peptide 19* by pinocytosis. The cells were incubated for 10 minutes at 37 °C with hypertonic 
loading solution (Influx, Life Technologies) containing 24 µM peptide and 1 mM sodium 
pervanadate, followed by pinosome lysis in hypotonic media to release the peptide into the 
cytosol and initiate the phosphorylation assay. The time at which the hypotonic media was 
applied was used at t=0 minutes. The cells were then pelleted and resuspended and incubated in 
full serum media containing 1 mM sodium pervanadate for 10 minutes at 37 °C. After the 10 
minutes, the cells were pelleted and washed twice and then resuspended with PBS buffer. The 
cells were lysed and intracellular activity terminated by heat treatment at 95 °C for 5 minutes. 
The resulting lysate was centrifuged at 14000 rcf for 10 minutes at 4°C, and the supernatant was 
collected and analyzed via CE-LIF without any further dilution. 
Capillary Electrophoresis 
CE-LIF (488 nm) was performed using a Proteome-Lab PA 800 (Beckman Coulter, Fullerton, 
CA) equipped with 30 cm fused silica capillaries of 30 µM inner diameter, 360 µM outer 
diameter (Polymicro Technologies, Phoenix, Az). All methods were run at 8kV for 20-40 
minutes. Electrophoretic buffer for all degradation assays was 100 mM borate, 100 mM sodium 
dodecyl sulfate (SDS), pH 7.7. Electrophoretic buffers for in vitro phosphorylation assays for 
peptides 1*, 17*, and 19* was 100 mM tris-tricine, 5 mM SDS, pH 8.1; for peptide 18* was 400 
mM borate, pH 9.5; for peptide 14* was 100 mM borate, 15 mM SDS, pH 11.3; for peptide 6* 
was 500 mM borate, pH 9.6. For all lysate and intracellular assays, the electrophoretic buffer was 
100 mM tris-tricine, 5 mM SDS, pH 8.1. In the case of phosphorylation of peptide 19* in cell 
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lysates, the peaks were de-convoluted by using a Lorentzian fit in Origin 9.0 (OriginLab 
Corporation, Northampton, MA) as described previously.44 
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Chapter III. Current Methods for Characterizing and Sensing Histone Posttranslational 
Modifications 
 
1. Packaging of DNA 
The DNA found within eukaryotic nuclei carries most of the genetic instructions used in the 
growth, development, and functioning of organisms. In humans, this DNA is composed of 23 
base-pairs of chromosomes, each comprising millions of base pairs of DNA, approximately 6 
billion in total. When stretched linearly, this 
amounts to roughly two meters of DNA, all stored in 
the nucleus that is only 10 µm in diameter.102 This 
requires a great deal of compaction, which is 
achieved through the wrapping of DNA into 
fundamental units called nucleosomes, which 
condense into chromatin, and can then coil tightly to 
form chromosomes (Figure 29).  
Each nucleosome consists of an octamer of four core histone proteins, H2A, H2B, H3, and 
H4, around which 147 DNA base pairs wrap. The nucleosomes are then connected by a linker 
region, composed of 20-30 base pairs.103 They can be in one of two states: one in which the DNA 
is wrapped around the histone tightly, and is inaccessible for transcription (heterochromatin), or 
one in which it is loosely associated, resulting in gene activation (euchromatin) (Figure 30). 
Figure 29. Representation of DNA packaging.  
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Which state it is in at any given time is determined by the various posttranslational modifications 
(PTMs) present on the histone proteins.  
 
2. Posttranslational Modifications 
The amino acid residues of histone proteins, especially of the unstructured tail domain, are 
subject to a large number of PTMs. These include the more common modifications, such as 
serine and threonine phosphorylation, arginine (mono- and di-) methylation, lysine (mono-, di-, 
and tri-) methylation, and lysine 
acetylation, as well as the less 
abundant modifications, such as 
proline isomerization, arginine 
deimination, ubiquitination, ADP 
ribosylation, and sumoylation (Figure 
31). These PTMs can act individually 
or in concert to dictate DNA 
packaging and distinct downstream events, either by recruiting non-histone proteins and enzyme 
complexes to chromatin, which subsequently manipulate DNA, or by interrupting nucleosomal 
contacts and consequently affecting the high-order structure of chromatin.2,104,105 As a result, 
Figure 30. Representation of heterochromatin and euchromatin. (Adapted from Sha, K. and Boyer, L. A. 
The chromatin signature of pluripotent cells (May 31, 2009), StemBook, ed. The Stem Cell Research 
Community, StemBook, doi/10.3824/stembook.1.45.1,http://www.stembook.org.) 
Figure 31. PTMs found at different sites on histone tails. ( Adapted 
from 167) 
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histone PTMs are implicated in a wide range of biological processes, including gene 
transcription, DNA replication and repair, mitosis, and meiosis.1 Consequently, dysregulation of 
histone PTMs is linked to various diseases, including cancer, asthma, and diabetes, among 
others, and can thus serve as valuable diagnostic indicators of disease progression.1,2 
3. Current Tools for Studying Histone PTMs 
Due to the biological ramifications of histone PTMs, there is great interest in mapping 
where, when, why, and how PTMs are installed and their subsequent downstream effects. The 
primary methods currently used to characterize PTMs require the use of antibodies as affinity 
reagents, which bring considerable limitations. They often suffer from a measurable amount of 
cross-reactivity, making it difficult to distinguish between distinct PTMs, such as different 
methylation states of lysine for example.106,107 This is a critical shortcoming, as each distinct 
methylation state leads to different downstream events. Furthermore, antibodies are time-
consuming, difficult, and expensive to produce, and quality, and thus efficacy, often varies from 
lot to lot.7,107 Finally, the sequence specificity of antibodies renders them futile for the discovery 
of new PTMs, and even binding to a known target site can be disrupted by PTMs at proximal 
residues. Several biomolecule-based designs, such as affibodies and aptamers, have shown 
potential as antibody surrogates.108,109 However, these systems are limited by sensitivity to pH 
and temperature, and like antibodies, binding is often not sequence independent. 
The use of mass spectrometry (MS) proteomics has emerged as a powerful platform for 
mapping histone PTMs. Since every PTM leads to a change in the element composition of a 
residue, each is associated with a defined mass shift (change in its molecular weight), and can 
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thus be identified by MS regardless of neighboring residues.110 
The most common approach to MS-based proteomics is the 
bottom-up approach. After isolation from cells or tissue, 
proteins are proteolytically digested, usually by trypsin, and the 
peptide fragments are analyzed by HPLC/MS/MS. The efficient 
detection of PTMs, however, is then highly dependent on the 
abundance of the PTM in a sample. In the proteolytic digest, the 
modified peptides are in very low abundance, thus requiring an 
enrichment step prior to analysis (Figure 32).111,112 Several 
enrichment methods are outlined below. 
Enrichment of Modified Fragments 
Many approaches for PTM enrichment have been established, and often vary based on the 
PTM of interest (Figure 33). The most effective PTM enrichment is that of phospho-peptides 
using immobilized metal affinity chromatography (IMAC) or metal oxide affinity 
chromatography (MOAC) (Figure 33). These methods take advantage of the unique chemical 
characteristics of the phosphate group-its negative charge and ability to interact with ion 
exchange beads and to participate in coordinate covalent bonding with metal ions. IMAC using 
Fe3+ was used to enrich phospho-peptides in some of the first successful phospho-proteomics 
studies,113,114 and has since been continually improved, with now an array of metal ions (i.e. 
Ga3+, Zr3+, Al3+) now available for use.110 MOAC has also been widely used, and currently 
represents an improvement over IMAC. A titanium oxide-based solid matrix has proven to be 
easier to implement and more robust for the analysis of complex protein samples,115 and its 
utility has been demonstrated in several proteomic studies.116–118 Both IMAC and MOAC have 
Figure 32. Work-flow of proteomic 
analysis of PTMs. Reproduced with 
permission from Wiley: Proteomics 
2009, 9 (20), 4632. 
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been applied to efficient proteomic studies, leading to the identification of tens of thousands of 
phospho-peptides.110 While extremely efficient, this method is specific to enriching 
phosphorylated peptides, and cannot be extended to other PTMs.  
 
Another approach often seen in the literature is one based on chemical-derivatization. One 
way this is done is via metabolic labeling. Azides are the most popular chemical handle for this 
purpose due to their small size and bioorthogonality. The chemically modified PTM proteins can 
then be conjugated to an affinity linker, such as biotin, for subsequent enrichment. This method 
has been successfully used towards enrichment of farnesylated,119 palmitoylated,120 and 
myristoylated121 proteins. Analogues of SAM have also been developed that allow the transfer of 
alkynes,122,123 and azides124 to lysine and arginine125 in place of a methyl group, in some cases 
requiring protein engineering to accommodate the 
unnatural SAM analogue.126,127 Alternatively, a PTM 
can be derivatized in vitro via chemical modification, 
converting it into a site for affinity labeling. For 
example, Wells et al. described the tagging of sites 
modified by O-linked β-N-acetylglucosamine (O-
GlcNAc) via mild β-elimination followed by Michael 
addition with biotin pentylamine for subsequent 
Figure 33. Examples of PTM enrichment methods for subsequent MS analysis. 
Figure 34. β-elimination of O-GlcNAc and 
replacement with BAP via Michael addition. 
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enrichment (Figure 34).128 The oxidation and conjugation of glycopeptides to hydrazide resin is 
another example of a commonly used derivatization method. Non-glycoproteins can be washed 
away, and the glycoproteins are subsequently released via enzymatic cleavage by peptide-N-
glycosidase F (PNGase F) (Figure 35).129,130 Recently, Lewallen et al. described a derivatization 
strategy to label citrullinated proteins. They developed a biotin-conjugated phenylglyoxal probe 
which, under acidic conditions, reacts selectively with citrulline. They went on to demonstrate 
the use of this probe as an antibody surrogate for western blotting and as a chemical handle to 
enrich citrullinated peptides for MS.131 The derivatization approach has been mostly applied to 
sugars and lipid-modified residues thus far. The development of selective reactions for less 
reactive modifications can be extremely challenging, and is lagging behind.110,112 Furthermore, 
although useful, chemical derivatization does have its drawbacks. Even the most efficient 
reactions suffer from some sample loss, and often produce unwanted side products that can 
further complicate analysis down the road. 
 
Figure 35. Chemical derivatization and subsequent enzymatic cleavage for enrichment of glycoproteins or peptides. Reproduced 
with permission from Wiley: Proteomics 2009, 9 (20), 4632. 
As an alternative to the derivatization approach, affinity based enrichment can be used. The 
most common example of that is antibody-based enrichment, perhaps the most widely used of all 
the approaches described thus far. The antibody corresponding to the PTM of interest can be 
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linked to a solid support and peptides from tryptic digest bearing that PTM can be isolated by 
immunoaffinity purification (Figure 33). Pan-PTM antibodies have been developed and used to 
study lysine acetylation,132–134 arginine methylation,135 and tyrosine nitration,136 among others. 
While antibodies have the advantage of being very specific, therefore alleviating the concern of 
inefficient separation, their specificity can also be problematic. Although “pan-antibodies” are 
commercially available, there are still cases in which the antibodies are affected by nearby 
residues.137,138 Their high cost and batch to batch variability can also be seen as a disadvantage, 
and is especially prominent when it comes to small PTMs, such as acetyl lysine or methyl lysine, 
since generating quality antibodies against them is difficult due to their similarity to their non-
modified counterparts.112 Furthermore, because of the generally tight binding of antibodies, 
release of the enriched peptides can often result in contamination of the sample with antibody 
fragments. 
Aside from antibodies, immobilized domains that can specifically recognize PTMs have 
gained traction. Lectins, for example, have the ability to specifically bind carbohydrates, and 
have been used for the isolation of glycoproteins or peptides (Figure 33).139–143 Triple malignant 
brain tumor domains of L3MBTL1, which sequence-independently recognizes mono- and di-
methylated lysine, was used to enrich mono- and di-methylated lysine containing peptides, with 
minimal sequence specificity compared to antibodies.144 This approach has also been taken with 
tandem-repeat ubiquitin-binding entities (TUBEs)145 and Macro domain146 to enrich 
ubiquitinated lysine and ADP-ribosylated proteins, respectively. More recently, interest has 
arisen in using small synthetic receptors as alternative affinity reagents.147,148 Various synthetic 
receptors able to recognize certain PTMs in a sequence independent manner have been and are 
continuing to be developed, including sulfonatocalix[n]arenes,149–151 mercaptophanes,3,152–154 and 
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cucurbit[7]uril (CB7),155 all of which have shown the ability to selectively bind methylated 
lysine and/or arginine, a class of PTMs that is particularly difficult to identify due to its small 
size. With their low cost, reproducibility, and stability to a range of conditions, synthetic 
receptors can serve as great tools for studying histone PTMs. 
4. Purpose of This Work 
In this work, one of the Waters’ group mercaptophanes, A2B,3 selective for trimethyllysine 
(KMe3), was used as an affinity reagent and applied towards affinity chromatography. 
Modification of one of the monomers, or the receptor as a whole, was done to anchor various 
linkers for immobilization on different resins. The effect of linkers and various buffers on the 
binding properties of A2B to various methylation states of lysine on a short histone peptide was 
analyzed, and finally, a column packed with resin bound A2B was used to successfully separate 
two peptides with the same sequence, differing only in the methylation of the lysine, 
demonstrating the feasibility of this approach. 
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Chapter IV. The Use of Small Molecule Receptors for Affinity Chromatography 
 
1. Waters Group Mercaptophanes 
As described in the previous chapter, improved methods for 
enriching protein samples in methylated Lys and Arg are greatly 
needed to move the field forward. The need to rely on 
antibodies, whether for directly studying the PTMs, or for 
enriching them for MS studies, is costing not only in money, but 
progress as well. The need for alternative methods is becoming 
more and more evident with the efforts to map the protein 
methylome. Protein methylation plays an integral role in cellular 
signaling, and yet it is poorly understood due to the lack of 
efficient tools to study it. This chapter describes the work done 
to apply a synthetic receptor towards the separation of peptides 
containing methylated lysine via affinity chromatography (Figure 36).  
Dynamic Combinatorial Chemistry (DCC) 
Figure 36. Affinity chromatography 
using a synthetic receptor for the 
separation of KMe3. 
55 
 
The design and synthesis of organic receptors, such as cucurbiturils,93,95,155 calixarenes,149–151 
and cyclophanes,156,157 can be quite challenging. The de novo design requires an exact 
knowledge of how the desired target binds to its native host, and even then is never a guarantee 
of a successful receptor for that target. Futhermore, macrocyclization is often very low 
yielding.156 Subsequent systematic changes to the structure are yet another challenge, with 
selective functionalization being yet again difficult and time consuming. Since many synthetic 
receptors contain multiple identical subunits in the macrocycle. To circumvent the need for de 
novo design and ease the re-design process, dynamic combinatorial chemistry (DCC) (Figure 37) 
has gained popularity in recent years as a high 
throughput method for synthesizing and identifying 
receptors. It uses thermodynamic control to produce 
a large library of potential receptors via reversible 
covalent bond formation. By mixing several 
monomers together, a large library of macrocycles forms under equilibrium. When an analyte is 
added, equilibrium shifts according to Le Chatelier’s principle, amplifying the most 
thermodynamically stable receptor.158–160 Thus the best host is discovered by competitive 
selection. This initial hit can then be used to further study the guest-host interactions by changing 
various aspects of the structure in an individual manner, one monomer at a time. This high 
throughput method allows for iterative redesign using simple and straightforward syntheses. 
Macrocyclic Receptor for Trimethyllysine 
Over the past several years, the Waters’ group has used DCC to study synthetic receptors for 
methylated lysine. Using disulfide exchange as their reversible reaction, and a short histone 
sequence as the guest, they developed a macrocyclic receptor, A2B (composed of monomers A & 
Figure 37. Cartoon representation of dynamic 
combinatorial chemistry (DCC). 
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B), that selectively binds K(Me3) over the lower methylation states of lysine (Figure 38 and 
Table 5). This receptor was found to have an affinity comparable to that of the HP1 
chromodomain, which is quite impressive, considering the size disparity between the two, and 
the added dependence of the chromodomain on the surrounding sequence.3 Several other such 
receptors (with selectivity towards KMe3) were reported by the Waters’ lab, such as A2N152 and 
A2D,
153 as well as by others, such as Sulfonatocalix[4]arene (CX4).150 While the use of these 
receptors was briefly attempted, the majority of the work outlined below was done using A2B, as 
it is the most straightforward to synthetically modify, and thus was used as a proof of concept. 
Table 5. Dissociation constants for the binding of A2B to 
Ac-WGGG-QTARKnSTG-NH2 (H3K9Men; n=0-3) as reported 
in the literature.152 The peptide sequence represents 
residues 5-12 of Histone 3, 3 glycines as spacers, and a 
tryptophan for concentration determination. All peptides 
were acetal capped and amidated at the C-terminus. 
 
 
 
 
 
 
 
2. Modification of Receptors for Attachment to Resin 
To begin this work, receptors had to be modified to create a point of attachment to a solid 
support. Looking at A2B, the easiest point to incorporate a linker was on the carboxylate of 
monomer B. The carboxylates were not thought to play a major role in the binding of KMe3, and 
the functionalization of one out of the five was not expected to dramatically affect the solubility. 
Peptide Kd (µM) Selectivity 
(relative to 
H3K9) 
H3K9Me3 2.6±0.1 8 
H3K9Me2 6.3±0.3 3.5 
H3K9Me1 13.9±0.1 1.6 
H3K9 22±1 -- 
Figure 38. Structure of A2B and 
monomers A & B. 
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Monomer B was expected to be easy to functionalize and incorporate into DCC libraries to form 
the modified receptor A2B. Monomers A and B, and the receptor A2B were all synthesized as 
previously reported in the literature.3,160 Several types of functionalization were explored as 
possible means for immobilization, as described below. 
FLAGtag 
The first linker appended onto monomer B was a FLAGtag peptide, with the intention of 
immobilizing the receptor on an anti-FLAG resin. The FLAGtag peptide was made on a 
microwave synthesizer, with 7 glycines added to the N-terminus to act as spacers. Monomer B 
was trityl protected to make Trt-B (Scheme 4), and an excess of the crude product was used to 
cap the peptide by hand using standard SPPS. After cleavage from resin and purification, the 
modified monomer, termed B-FLAG was put in a biased DCC library to form A2B-FLAG 
(Scheme 5). The library was analyzed by LC/MS, and after two days, rac- and meso-A2B-FLAG 
can be seen as the major product (Figure 39). 
 
Scheme 4. Synthesis of Trt-B. 
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Scheme 5. Synthesis of A2B-FLAG. 
 
Figure 39. LC/MS trace of a biased A2B-FLAG DCC library at 2 days. Run in a gradient from 5 to 80% B; solvent A=0.2% FA/H2O; 
Solvent B=0.2% FA/ACN. 
Upon purification, ITC was used to test the binding of A2B-FLAG to H3K9Men peptide 
guests (the same peptides used with A2B). The loss of the carboxylate on monomer B weakened 
the binding of the receptor to all peptides, but the selectivity remained comparable (Table 6), 
altogether confirming the minor role of the carboxylate in binding. For these purposes, one can 
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argue the weakened binding is an advantage, as H3K9Me and H3K9 now don’t bind at all, 
potentially improving separation. 
Table 6. Dissociation constants for the binding of A2B-FLAG to Ac-WGGG-QTARKnSTG-NH2 (H3K9Men; n=0-3) as measured by 
ITC.a The peptide sequence represents residues 5-12 of Histone 3, 3 glycines as spacers, and a tryptophan for concentration 
determination. 
Peptide Kd (µM) Selectivity (relative to H3K9) 
H3K9Me3 13.2±1.1 > 10 fold 
H3K9Me2 35.9±4.3 > 4-fold 
H3K9Me >150 -- 
H3K9 >150 -- 
a Conditions: 26 °C in 10 mM borate buffer, pH 8.5. Error is the standard deviation from 3 runs. 
Once the binding ability of A2B-FLAG was confirmed, experiments were undertaken to 
immobilize it on an anti-FLAG resin. This was done by first combining the A2B-FLAG with the 
resin, then adding a reducing agent to release monomer A. Measurement of the released 
monomer indicated the amount of receptor that has been immobilized. The anti-FLAG resin (100 
uL slurry) (obtained from the Chen lab; purchased from Sigma-Aldrich) was incubated with 
A2B-FLAG (300 uL of 230 uM solution in in 1X PBS buffer (pH 7.4)) for 5 hours at 2-8°C (per 
instructions from the resin manufacturers). The resin was then washed several times with 1X 
PBS buffer and agitated in excess 0.1M glycine•HCl buffer (pH 3.45) for elution of the receptor 
(per manufacturers’ instructions). The rapid drop in pH is expected to disrupt the binding 
interactions, allowing for the release of the A2B-FLAG from the resin. This was done twice, 
ensuring the most stringent elution conditions. It is worth noting that at this point, the resin had 
lost most of its color, suggesting the elution conditions were doing more than just eluting the 
receptor off the resin. The remaining resin was then washed with 1X PBS buffer and incubated 
with TCEP in 1X PBS buffer for 2.5 hours. The three supernatant solutions (the two rounds of 
acid elution, and the TCEP elution) were then concentrated and analyzed by analytical HPLC. As 
can be seen from the HPLC traces, no A2B-FLAG nor monomer A could be seen (Figure 40), 
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suggesting A2B-FLAG never successfully bound to the resin in which case it is unclear if the 
problem was with the receptor, or the resin itself. One possibility is that the glycine spacer 
incorporated into the receptor was not long enough, and disrupted the recognition of the FLAG-
epitope by the anti-FLAG antibody. In addition, the problems with antibodies discussed above 
still apply in this case, and it cannot be entirely ruled out that this was simply a bad batch. 
Alternatively, it is possible the amounts recovered were too small to detect by the methods 
available to us. Tests run prior to these experiments determined the limit of detection of the 
analytical HPLC used was rather close to the expected concentration of receptor if fully eluted 
off the resin; so incomplete binding or elution would have been undetectable. Unfortunately, not 
enough resin was available at the time to work with increased concentrations. Several other 
immobilization options were pursued as described below, and this approach was not investigated 
further 
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Figure 40. HPLC traces of (A) Glycine•HCl buffer elutions (blue and black) and solution of A2B-FLAG in glycine•HCl buffer (green); 
(B) PBS buffer blank (light blue), TCEP in PBS buffer (green), and TCEP+monomer A in PBS buffer (dark blue), TCEP elution 
(black). All traces were run at 0100% B in 60 mins; A=0.1%TFA/H2O, B=0.1%TFA/ACN. 
Amine Linker 
To avoid the use of antibodies, the direct attachment of receptor to resin was investigated. An 
amine functionality was chosen, for conjugation onto NHS-activated agarose resin (purchased 
from Bio-Rad). Due to the sterics at the carboxylates of A, they have been found to be quite 
unreactive,161 so cross-linking of receptors was not expected to be a problem. Trt-B was 
activated for coupling by forming the NHS ester (Trt-B-NHS). N-Boc-1,4-butanediamine was 
then coupled on, followed by a TFA global deprotection to yield the monomer termed B-NH2 
(Scheme 6). Upon use of this monomer in a DCC library biased towards A2B-NH2, however, 
nothing but the free monomers was seen (Figure 41). The same issue has been observed by 
another group member when amino groups were incorporated into the monomers.162 
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Scheme 6. Synthesis of B-NH2. 
 
Figure 41. LC/MS trace of a biased A2B-NH2 library. Run in 1090%B in 25 mins; A/B=NH4OAc in H2O/ACN. 
Since this problem was not previously seen with A2B or A2B-FLAG, it was assumed this 
was specifically due to the presence of the amine. To try to circumvent this issue, an Fmoc 
protected version of the monomer, B-NH2-Fmoc, was synthesized (Scheme 7). The fully 
protected intermediate, was unable to be purified by standard column chromatography, as the 
slightly acidic silica removes the trityl groups, while treatment of the silica with base prior to 
usage causes the removal of the Fmoc group. As such, the final deprotection was carried out on 
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the crude product, and the final B-NH2-Fmoc monomer was purified by HPLC in NH4OAc 
buffer. Oddly enough, while the 1H NMR of the purified product appeared clean, there were no 
peaks for the aromatic ring, leaving a spectra that looks much like that of the N-Fmoc-1,4-
butanediamine alone. However, the mass of N-Fmoc-1,4-butanediamine did not appear by ESI-
MS, and the late retention time of the product on the HPLC (24 mins) is highly un-characteristic 
of a free amine. TLC comparison was unhelpful, as both stuck to the baseline, but ESI-MS 
confirmed that the major mass seen is that of monomer B-NH2-Fmoc. 
 
Scheme 7. Synthesis of B-NH2-Fmoc. 
B-NH2-Fmoc was then put into a DCC library templated by Me-Isoquinoline. For this 
library, 5:3 THF:DMSO was used instead of water, due to the insolubility of any B-NH2-Fmoc 
macrocycles that may form. The library was analyzed by LC/MS as before, and the same trace 
was seen on day 5, 7, and 13 (Figure 42). Many species appeared to be present, but the only 
identifiable mass was that of monomer A. Oddly enough, it eluted around 8 mins, while free A is 
known to elute within the first minute or two, so its identity remained in question, despite the 
mass seen. It appeared that despite the protection of the amine functionality, the synthesis of the 
receptor bearing the amine functionality was simply un-favorable, and further optimization was 
not attempted. Instead, direct attachment was envisioned via activation of un-modified receptor 
and conjugation onto an amino-sepharose resin (see section 4.1 below).  
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Figure 42. LC/MS trace of biased A2B-NH2-Fmoc library (3.3 mM B-NH2-Fmoc, 6.6 mM A, and 10.4 mM Me-Isoquinoline in 5.5 
mL 5:3 THF:DMSO) after 7 days. Run in a gradient of 10-90%B in which A=0.2% FA/H2O and B=0.2% FA/ACN. 
Biotinylated Receptors 
Biotin is one of the most commonly used recognition motifs due to its picomolar affinity to 
avidin and streptavidin. Various resins are commercially available for the immobilization of 
biotinylated molecules, and this represented another feasible approach for our system. Instead of 
modifying monomer B as before, biotinylation was carried out directly on A2B. The biotinylated 
derivative was synthesized using a short polyethylene glycol (PEG) diamine linker (Biotin-
PEG3-NH2), as reported in the literature (Scheme 8).
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Scheme 8. Synthesis of A2B-PEG3-Biotin. 
To immobilize the biotinylated receptor, A2B-PEG3-Biotin was incubated with NeutrAvidin 
agarose resin (purchased from Thermo Scientific) for one hour in 1X PBS buffer (pH 7.4) at 2-
8°C (per instructions from the resin manufacturers). The resin was then washed several times 
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with 1X PBS buffer and agitated in 8 M guanidine•HCl buffer (pH 1.5) for elution of any 
unbound receptor. The remaining resin was then washed with 1X PBS buffer, followed by TCEP 
in 1X PBS buffer. The incubation solution, washes, and eluted solutions were all analyzed by 
HPLC (Figure 43). No A or A2B-PEG3-Biotin were seen in any of the solutions, including the 
incubation solution, which is known to have contained a large excess of A2B-PEG3-Biotin. 
 
Figure 43. HPLC traces of (A) 1X PBS buffer (red), A2B-PEG3-Biotin/PBS buffer (black), incubation solution (green), post-
incubation washes (light blue), and acid elutions (pink); (B) 1X PBS buffer (black), monomer A+TCEP in PBS buffer (blue), TCEP 
elution (green). 
In light of these results, a sample of A2B-
PEG3-Biotin was given to the Strahl lab to 
confirm its ability to bind to avidin. Dot-blot 
confirmed that the biotin tag can still be 
recognized (Figure 44), and this approach was 
deemed feasible. 
3. Additional Binding Studies 
Figure 44. Dot-blot assay with A2B-PEG3-Biotin. 
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Before proceeding with the use of the receptors for affinity chromatography, further studies 
were done to determine the effect of the synthetic modifications and buffer conditions on the 
binding of the receptors to peptides. Since we envisioned beginning with the separation of only 
H3K9 and H3K9Me3, the binding only to those two peptides were tested. Initial attempts to 
measure the binding of A2B-PEG3-Biotin were done using fluorescence polarization, as reported 
in the literature for A2B, using FAM-QTARKMenSTG-NH2 .
3 As a control, the binding of the 
peptide to un-modified A2B was tested as well, and surprisingly no binding was seen to the 
KMe3, which in the literature was reported to bind this peptide with a Kd of 25±3 µM. ITC was 
then used, and A2B was found to bind to the peptide with a Kd of 14.8±0.6 µM, which is higher 
than that previously seen when using ITC to measure binding to Ac-WGGG-QTARKMe3STG-
NH2 (H3KMe3).
152 When H3KMe3 was tested, a comparable Kd was observed, suggesting the 
FAM-cap was weakening the binding, or possibly the lack of a spacer between it and the H3 5-
12 sequence. Due to this discovery, all binding studies from this point forward were done using 
ITC. Using this method, A2B-PEG3-Biotin showed no substantial binding to H3K9Me3 (Kd>150 
µM). To test whether this was due to the proximity of the biotin to the binding site, A2B-PEG11-
Biotin was synthesized. It did not, however, restore binding. It was hypothesized that perhaps the 
biotin is somehow occupying the binding pocket, since not all modifications seem to have this 
effect (see A2B-FLAG). If that was indeed the case, that problem should be alleviated once the 
receptor is displaced by avidine (as in our intended system), since it is doubtful this A2B:biotin 
interaction is stronger than that of biotin with avidine. Since applying this to affinity 
chromatography will undoubtly require screening buffers, it was decided it would be 
advantageous to first carry out a comprehensive salt study on the receptors prior to any 
modification. 
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Salt Study 
A salt study was done on both A2B and A2D
153 (Figure 45), a receptor previously reported by 
our lab to bind asymmetric dimethyl arginine (aR(Me2)) with high selectivity over un-modified 
arginine. The binding affinity of each receptor to a peptide that is either un-modified, or contains 
the modification relevant to that receptor, was measure by ITC in buffers containing differing 
amounts of NaCl (Table 7). For both receptors, increased concentrations of salt weakened the 
binding of both peptides, but had a greater effect on the binding of the un-modified peptide than 
that of the modified one, suggesting electrostatics played a much bigger role in the binding of the 
un-modified peptides. This can be advantageous to affinity chromatography; at certain salt 
concentrations, the un-modified peptide no longer binds to the receptor, while the modified one 
still does so with reasonable affinity that allows for release from the resin without the need for 
harsh conditions. 
 
Figure 45. A2B and A2D. 
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Table 7. Dissociation constants for the binding of A2B and A2D to Ac-WGGG-QTARKnSTG-NH2 (n=0 or 3) or Ac-YGGG-QTAXKSTG-
NH2 (X=R or aR(Me2)) as measured by ITC.a The peptide sequences represent residues 5-12 of Histone 3, 3 glycines as spacers, 
and a tryptophan or tyrosine for concentration determination. 
 
 
 
 
 
 
 
 
 
 
 
 
 
aDetermined by ITC at 26°C in 10 mM borate buffer, pH 8.5, with varying concentrations of NaCl. Errors are the 
standard deviation of two runs. bData reported by Pinkin and Waters.1 cData reported by James et. al..2 
4. Affinity chromatography 
Direct Attachment 
The first method attempted to immobilize receptors was via direct attachment. Since the 
synthesis of an amine functionalized A2B was unsuccessful, we looked to attach un-
functionalized A2B to an amino-sepharose resin (purchased from GE Healthcare). CX4, another 
well studied receptor that is known to selectively bind KMe3, was attached as well, via NHS 
activation (to form CX4-NHS), followed by addition of the resin to the crude reaction mixture. 
Entry Guest Receptor NaCl Concentration (mM) Kdissoc (µM)a 
1b Ac-WGGG-QTARKSTG-NH2 A2B 0 22±1 
2   30 ≥85 
3   90 ≥180 
4   120 ≥280 
5   150 ≥280 
6 b Ac-WGGG-QTARK(Me3)STG-NH2  0 2.6±0.1 
7   30 12.6±0.9 
8   60 12.8±0.02 
9   90 23.9±0.7 
10   120 26.4±0.7 
11   150 ≥45 
12c Ac-YGG-QTARKSTG-NH2 A2D 0 ≥60 
13   30 ≥115 
14   60 ≥140 
15   90 ≥205 
16   120 ≥270 
17   150 ≥365 
18c Ac-YGG-QTA-aR(Me2)-KSTG-NH2  0 5.1±0.1 
19   30 11.4±0.3 
20   60 18.1±1.8 
21   90 29.9±2.9 
22   120 34.9±3.6 
23   150 ≥55 
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A2B was attached using standard amide coupling procedure (Scheme 9). The efficiency of the 
coupling was determined by Kaiser test. 
 
Scheme 9. Attachment of CX4 and A2B to amino-sepharose resin. 
In both cases, the resin appeared to shrink upon attachment of the receptors. This is 
problematic for affinity chromatography, as the peptides run through such a column would not 
be able to properly interact with the receptors. None-the-less, columns were packed with CX4-
Sepharose resin and A2B-Sepharose resin and a 1:1 mixture of H3K9 and H3K9Me3 (50 uL 
peptide solution, 5 uM of each/0.3 mL column) were run through them in 3 different solvents: 10 
mM borate buffer (pH 8.5), 10 mM phosphate buffer (pH 7.4), and unbuffered mQ water. Three 
column volumes were collected from each column and given to the Chen lab for MS analysis. 
Each columns was washed with acetonitrile at the end and that sample was dried down and given 
for analysis as well. For both receptors, under all conditions tried, both peptides were barely, if at 
all, detectable. With the sensitivity of the instrument used being orders of magnitude lower than 
the concentrations used here, these peptides should be detectable even with the dilution incurred 
from running through the column. This suggested that the peptides were sticking to the resin, and 
this immobilization strategy was incompatible with the goals envisioned. 
Attachment via Biotin 
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With confirmation that A2B-biotin binds NeutrAvidin in a dot-blot, along with the fact that 
the NeutrAvidin resin remained swelled after incubation with A2B-biotin, we moved forward 
with the use of the immobilized A2B-biotin on NeutrAvidin agarose resin, as it seemed to have 
the most promise. In designing an effective technique, the two requirements were to maximize 
selectivity, and to develop conditions for separation that were in line with the standard 
procedures for MS analysis. We envisioned using 
a protocol described by Lin and Garcia, in which 
histone proteins are taken through a 
propionylation step prior to trypsin digestion, and 
again after, before enrichment and subsequent 
MS analysis (Scheme 10).163 The first 
propionylation step caps any un-methylated 
lysines, thereby lessening the number of cleavage 
sites and preventing the formation of exceedingly 
small, hydrophilic fragments that would be 
difficult to detect. Based on previous studies of 
our receptors,3 as well as the results of the salt 
studies above, we postulated that such capping of 
the un-modified lysines would enhance the 
selectivity of our receptors by reducing non-specific electrostatic interactions, and decreasing the 
binding affinity of the un-methylated (now propionylated) fragments to A2B. The second 
propionylation step would cap the N-terminus of the newly formed fragments, thereby serving 
the same purposes. Our goal is to then take the propionylated and digested sample and run it 
Scheme 10. Envisioned work-flow for derivatization and 
digestion of proteins prior to MS analysis.163 R1 and R2 
represent any amino acids other than lysine and arginine. 
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through the receptor-bound columns to achieve enrichment of fragments containing methylated 
lysines. For initial experiments, model peptides were chosen that would represent a typical 
fragment formed by this propionylation and digestion of Histone 3. Residues 3-8 of Histone 3 
(H3 3-8) would be one of the fragments formed under such conditions, since trypsin would 
cleave at the carboxyl side of only arginines in this scenario. Two versions of this peptide were 
synthesized-one in which lysine 4 is propionylated (prop-H3K4prop) and one in which it is 
trimethylated (prop-H3K4Me3). Both peptides contained 3 glycines as spacers and a tryptophan 
for concentration determination at the N-terminus, and the N-terminus of both was capped with a 
propionyl group (Figure 46). Measurement of the binding affinity of A2B to these peptides 
showed the predicted results: prop-H3K4Me3 bound to A2B with a Kd of 8.8±0.05 µM, while 
prop-H3K4prop showed no binding (Table 8). 
 
Figure 46. Model peptides prop-H3K4prop and H3K4Me3. K4 is highlighted in red. 
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Table 8. Dissociation constants for the binding of prop-H3 3-8 peptides to A2B as measured by ITC.a 
 
 
 
 
aConditions: 26 °C in 10 mM borate buffer, pH 8.5. Error is the standard deviation from 2 runs. 
Initial Results 
Since synthesis of the acetylated versions of the propionylated model peptides (where all 
propionyl groups were replaced with acetyl groups; from here on referred to as H3K4Men) were 
higher yielding, and the acetyl capping was expected to have the same effect as the 
propionylation, all following experiments were performed with the acetylated peptides. An initial 
set of three buffers were chosen to test on the A2B-NeutrAvidin columns: 1 mM and 10 mM 
phosphate buffers (pH 7.4), since phosphate buffers at neutral pH are quite common for handling 
biological samples, and 10 mM borate buffer (pH 8.5), since this buffer was used in all previous 
binding studies of receptors, and would thus best reflect the expected behavior. For 
quantification by MS, standard solutions of varying ratios of H3K4Ac and H3K4Me3 were made 
and analyzed by LC-MS/MS (all LC-MS/MS was done by Ling Xie, Chen lab) to construct a 
calibration curve; one for each of the initial buffers to be used (Figure 47). 
Peptide Kd (µM) 
Prop-H3K4prop >200 
Prop-H3K4Me3 8.8±0.05 
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Figure 47. Calibration curves for 1 mM phosphate buffer (pH 7.4), 10 mM phosphate buffer (pH 7.4), and 10 mM borate buffer 
(pH 8.5). 
Three columns packed with A2B-NeutrAvidin resin were loaded with a 1:1 mixture of 
H3K4Me3 and H3K4Ac in the elution buffer and run in parallel. Five fractions (1 column 
volume each) were collected from each, and analyzed by LC-MS/MS. In both phosphate buffers, 
the peptides peaked in different fractions, with H3K4Me3 being the later eluting of the two, 
suggesting some separation was taking place as expected. While H3K4Ac eluted entirely in the 
first 2 fractions, H3K4Me3 peaked in fraction 2, with ratios of 2:1 and 6:1 (H3K4Me3:H3K4Ac) 
in 1 mM and 10 mM phosphate buffer, respectively. In the borate buffer, however, H3K4Ac was 
seen peaking at the second fraction (much like H3K4Me3 did in the phosphate buffers), while 
H3K4Me3 did not appear to elute off the column at all within the 5 fractions collected, 
suggesting it remained bound on the immobilized receptor (Figure 48). 
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Figure 48. Elution patterns of H3K4Me3 and H3K4Ac in different buffers analyzed by LC-MS/MS. 
Based on the results of the salt study conducted on A2B, following the elution of H3K4Ac 
with a high salt buffer should weaken the binding of H3K4Me3 to A2B and release it from the 
resin. When 10 mM borate+120 mM NaCl buffer (pH 8.5) was added after the initial elution, 
H3K4Me3 then eluted from the column and peaked at fraction 6, the first fraction collected after 
switching to the high salt buffer. It continued to elute from the column thereafter, reaching up to 
50:1 H3K4Me3:H3K4Ac. No such enrichment was seen when a column devoid of A2B was used 
(Figure 49). 
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Figure 49. Enrichment of H3K4Me3 with and without A2B. 
5. Conclusions and Ongoing Work 
The separation of a trimethyllysine containing peptide from its acetylated counterpart using a 
synthetic receptor was demonstrated. In light of these promising results, work is currently being 
done to apply this technique to more complex peptide mixtures; ones that more closely mimic 
digested proteins. A mixture of model peptides based on residues 27-45 of Histone 3 (from the 
Strahl lab) (Figure 50. H3 27-45 peptides. Lysine 36 is highlighted in red.) were taken through 
the propionylation-digestion-propionylation procedure described by Lin and Garcia,163 followed 
by desalting, and column separation. If enrichment of the fragment containing trimethyllysine is 
seen here, this can potentially be taken on to digested proteins. This separation approach 
represents an advantage over currently used antibody-based approaches, as it requires much 
milder conditions for release, is reproducible, and far cheaper. The ability to detect PTMs is 
highly dependent on their separation from more abundant, un-modified residues, and a simple 
procedure such as the one developed here can greatly facilitate the mapping of PTMs in the 
human proteome, further narrowing the current gap in knowledge. 
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6. Experimental 
Peptide Synthesis and Purification 
Peptides were synthesized using manual or automated standard solid phase peptide synthesis 
(Thuramed Peptide Synthesizer, or CEM Liberty 1 Microwave Peptide Synthesizer) using Fmoc 
protected amino acids on 0.057 mmol of RINK Amide resin or CLEAR-Amide resin. Four 
equivalents of standard amino acids, or 2 eq. of specially modified amino acids (Fmoc-KAc-
CO2H, Fmoc-K(Alloc)-CO2H), were used for each peptide coupling. The amino acid residues 
were activated for coupling with HBTU and HOBt in the presence of DIPEA in DMF. The N-
terminus was acetyl capped, propionyl capped, or capped with (5,6)-FAM. Peptides were 
acetylated at the N-terminus by treating the resin with 5% acetic anhydride and 6% 2,6-lutidine 
in 5 mL of DMF bubbling with N2 for 40 minutes. Propionic acid was coupled to the N-terminus 
as a specially modified amino acid (see above). (5,6)-FAM was coupled to the N-terminus using 
4 equivalents of (5,6)-FAM, 5 equivalents of PyBOP/HOBt and 8 equivalents of DIPEA in DMF 
and allowed to bubble with N2 overnight. 
 
Propionylation of lysine was done by coupling an Alloc protected lysine as a specially modified 
amino acid (see above). After capping of the N-terminus, an Alloc deprotection was carried out 
in 1:2 DCM:ACN in the presence of Pd(OAc)2 (0.3 eq.), PPh3 (1.5 eq.), NMM (10 eq.), and 
PhSiH3 (10 eq.). Care was taken to ensure the PhSiH3 was the last reagent added. The reaction 
H3K35: KSAPSTGGVKKPHRYKPGT-GG-K(Biotin)-NH2 
H3K35Me3: KSAPSTGGVK(Me3)KPHRYKPGT-G-K(Biotin)-NH2 
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Figure 50. H3 27-45 peptides. Lysine 36 is highlighted in red. 
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was agitated over-night. After draining the solution, the resin was washed with THF (1 x 5mL x 
5mins.), DMF (2 x 5 mL x 2 mins.), sodium diethyldithiocarbamate trihydrate solution (25 mg/ 1 
mL DMF) (4-5 x 5 mL x 10 mins.), DMF (2 x 5 mL x 2 mins.), and DCM (2 x 5 mL x 5 mins.). 
Finally, propionic acid was coupled to the ε-NH of lysine using standard coupling conditions. 
 
Peptides were cleaved from the resin in 9.5:2.5:2.5 trifluoroacetic acid (TFA), TIPS and water 
respectively for 3-4 hours. The TFA was evaporated and the cleaved peptides were precipitated 
using cold ethyl ether and extracted with water. Extracted peptides were lyophilized and then 
purified using semi-preparative RP-HPLC on a Vydac C18 semipreparative column with a 
gradient from ‘0 to 100% B’ in 45-120 minutes. Solvent A was 95% H2O, 5% CH3CN and 0.1% 
TFA and Solvent B was made of 95% CH3CN, 5% H2O and 0.1% TFA. Purified peptides were 
lyophilized and their purity confirmed by Analytical LC/MS on an Agilent Rapid Resolution LC-
MSD system, equipped with an online degasser, binary pump, autosampler, heated column 
compartment, and diode array detector. 
Synthesis of monomers A, B, and D 
Synthesized as previously reported in literature.3,152–154,160 
Synthesis of Trt-B 
 
To a mixture of monomer B (0.6103 g, 3.28 mmol), TrtCl (1.8270 g, 6.55 mmol), and 
TCEP·HCl (unmeasured-tip of a spatula) was added dry DCM to form a cloudy suspension. The 
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reaction was let stir under nitrogen for 30 minutes at room temperature, at which point it was a 
clear yellow solution. The solution was washed with water, dried over MgSO4, and concentrated 
in vacuo to yield the product as a white solid. The crude product was carried on as is to 
proceeding reactions. 
Synthesis of Trt-B-NHS 
 
Trt-B was synthesized as described above. 
Crude Trt-B (0.894 g), NHS (0.0193 g, 0.17 mmol), and DCC (0.0336 g, 0.16 mmol) were 
dissolved in dry DCM and let stir under nitrogen for 1 hour at room temperature. The resulting 
precipitate was filtered and concentrated in vacuo to yield white solids. The product was purified 
by column chromatography in DCM to yield the product as a white solid (0.0391 g, 59.3% yield 
over 2 steps). 1H NMR ((CD3)CO) δ 7.21-7.51 (m, 33H), 2.84 (d,4H). 
Synthesis of B-FLAG 
Peptides were synthesized by automated solid phase peptide synthesis on an CEM Liberty1 
Microwave Peptide Synthesizer using Fmoc protected amino acids on a Clear-Amide resin. The 
amino acid residues were activated for coupling with HBTU and HOBt in the presence of 
DIPEA in DMF. 2 x 15 minute cycles were used for each amino acid coupling step. 
Deprotections were carried out in 20% piperazine in DMF for approximately 2 x 5 minutes. The 
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N-terminus was capped with Trt-protected B, which was coupled the same way described above 
but for 5 hours. Cleavage of the peptide from the resin was performed in 95:5:2.5:2.5 TFA: 
EDTA: TIPS: water for 3-4 hours. TFA was evaporated and cleavage products were precipitated 
with cold ether. The peptide were extracted with water and lyophilized. The peptide was purified 
by reversed phase HPLC, using a Vydac C-18 semi preparative column and a gradient of 0 to 
100% B in 45 minutes, where solvent A was 10mM NH4OAc in water and solvent B was 10mM 
NH4OAc in acetonitrile. Once purified, the peptide was lyophilized to powder and peptide 
identity was confirmed by MALDI-MS [M-H+]: expected 1579.54, observed 1580. 
Synthesis of B-NH2 
 
4-Boc-1,4-diaminobutane (0.02 mL, 0.10 mmol) was added to a solution of Trt-B-NHS (0.0596 
g, 0.08 mmol) in 5:1 ACN:DCM. DIPEA (0.02 mL, 0.12 mmol) was added and the solution was 
let stir under nitrogen  overnight. Ethyl acetate was added and the organic solution was 
transferred to a separatory funnel and washed with sat. aq. Na2CO3 (2x), H2O (2x), and brine. 
The organic layer was dried over MgSO4 and concentrated in vacuo to yield the product as white 
solids (0.0407 g, 62%). 1H NMR ((CD3)CO) δ 6.93-7.34 (m, 33H), 6.02 (bs, 1H), 3.26 (q, 2H), 
3.12 (q, 2H), 1.53 (m, 4H), 1.49 (s, 9H). 
The above product (0.0377 g, 0.045 mmol) was dissolved in DCM and purged with nitrogen. 
Excess TFA (1.4 mL, 18.3 mmol) was added dropwise, followed by the addition of excess TIPS 
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(0.27 mL, 1.318 mmol). The reaction was let stir at room temperature for one hour. The product 
was extracted with degassed NH4OH (2% in water) and the solution was acidified with glacial 
acetic acid and lyophilized to give the product as a white solid. Product identity was confirmed 
by HR ESI-MS ([M+H+]: expected 257.07, observed 257.09). Yield was not determined due to 
the presence of salts. 
Synthesis of B-NH2-Fmoc 
 
B-NH2-Fmoc was synthesized in the same way as B-NH2 using 4-Fmoc-1,4-diaminobutane with 
the following exceptions: The crude fully protected intermediate was carried on without any 
purification. The final product was purified by reversed phase HPLC, using a Vydac C-18 semi 
preparative column and a gradient of 0 to 100% B in 45 minutes, where solvent A was 10mM 
NH4OAc in water and solvent B was 10mM NH4OAc in acetonitrile. Once purified, the product 
was lyophilized to powder and the identity of the compound was confirmed by HR ESI-MS. 
([M-H+] 477.19). Yield was not determined due to the presence of salts. 
Synthesis and purification of A2B and A2D 
Synthesized as previously reported in literature.3,153,160 
A2B and A2D salt study (* all ITC experiments were run as described at the end of this section) 
 A2B + H3K9 
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 A2B + H3K9/Me3 
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 A2D + H3R8 
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 A2D + H3aR8Me2 
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Synthesis and purification of A2B-FLAG, A2B-PEG4-N3, A2B-NH2 and A2B-NH2-Fmoc 
Synthesized as A2B (see above), replacing monomer B with B-FLAG, B-NH2, B-NH2-Fmoc, or 
B-PEG4-N3. In the case of A2B-NH2-Fmoc, 5:3 THF:DMSO was used as the solvent instead of 
buffered water. A2B-FLAG and A2B-PEG4-N3 were purified as described above for A2B, and 
characterized by MALDI-MS. 
A2B-FLAG: [M-H
+] expected 2286.36, observed 2287. 
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A2B-PEG4-N3: [M-H
+] expected 1136.12, observed 1135. 
A2B-FLAG binding studies 
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Synthesis of A2B-PEGn-Biotin 
Synthesized as previously reported in literature,161 with the exception that commercially 
available biotinylated PEG was used. 
A2B-PEGn-Biotin binding studies to H3K9Me3 
 
Synthesis of CX4-NHS 
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CX4 (made as previously described in the literature)164 (0.00559 g, 7 µmol) and NHS (0.00097 
g, 8 µmol) were dissolved in dry DMF (0.2 mL) and molecular sieves were added. DIPEA (1 µL, 
6 µmol) was added, followed by DIC (1.5 µL, 9 µmol) and the solution was let stir for 2 hours. 
NHS (0.00097 g, 8 µmol) was again added, and the reaction was let stir for an additional 2 hours. 
The crude reaction mixture was then used to attach to resin as outlined below. 
Attachment of CX4 to Sepharose resin 
 
0.3 mL of H2N-Sepharose resin was let incubate in the crude CX4-NHS reaction mixture over 
night. The incubation solution was decanted, and the resin washed with DMF, DCM, MeOH, 
H2O, and the buffer to be used for elution. 
Attachment of A2B to Sepharose resin 
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0.3 mL of H2N-Sepharose resin was let incubate in a solution of A2B (0.005 g, 5.6 µmol), HCTU 
(0.0099 g, 23.9 µmol), and DIPEA (8.4 µL, 48.2 µmol), in DMF overnight. The incubation 
solution was decanted, and the resin washed with DMF, DCM, MeOH, H2O, and the buffer to be 
used for elution. 
Immobilization of A2B-PEG3-Biotin onto NeutrAvidin agarose resin 
0.25 mL of resin slurry (Pierce Neutravidin Resin; Thermo Scientific, catalog # 29204) was 
centrifuged and the supernatant was decanted. The resin was washed with 1X PBS buffer (3 
times), and 0.6 mL of 50 µM A2B-PEG3-Biotin in 1X PBS buffer was added and let incubate 
over night at 4 °C. The resin was then washed with 1X PBS buffer (3 times), followed by water 
(3 times). 
Affinity Chromatography with A2B-PEG3-Biotin on NeutrAvidin Agarose Resin 
A2B-PEG3-Biotin bound resin was prepared as outlined above, and 0.25 mL were packed into a 
1 mL plastic column. The resin was washed with 3 column volumes of 10 mM borate buffer (pH 
8.5), and 25 µL of 5 uM H3K5Me3 and 5 uM H3K5prop in 10 mM borate buffer (pH 8.5) were 
loaded onto the column. 10 mM borate buffer (pH 8.5) (5X column volume), followed by 10 
mM borate+120 mM NaCl buffer (pH 8.5) (5X column volume) were run through the column, 
and fractions were collected (1 column volume/fraction). 
For the negative control, the column was packed with NeutrAvidin Agarose resin (not bound to a 
receptor). 
All collected fractions were lyophilized and desalted (as described in literature165) prior to LC-
MS/MS analysis. 
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ITC Binding Studies 
All ITC titrations were performed using a MicroCal AutoiTC200 at 26 °C. Data analysis was 
performed using the built in Origin 7 software using a one site binding model. A 10 mM pH 8.5 
sodium borate buffer was used for all experiments. All concentrations were determined using a 
NanoDrop2000 with a xenon flash lamp, 2048 element linear silicon CCD array detector, and 1 
mm path length. ∼1.1–2.4 mM solutions of peptide were titrated into ∼100–180 μM solutions of 
receptor using 2 μL injections every 3 minutes. Heats of dilution of peptides were subtracted 
prior to analysis in Origin. 
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